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ABSTRACT 
 
Effect of Catalase/Superoxide Dismutase Mimetic EUK-134 on Damage, Inflammation, 
and Force Generation of the Diaphragm Muscle in mdx Mice. (August 2009) 
Jong Hee Kim, B.Ed., Seoul National University; 
M.Ed., Seoul National University 
Chair of Advisory Committee: Dr. John M. Lawler 
 
Duchenne muscular dystrophy (DMD) is the most devastating form of muscular 
dystrophy caused by a mutation in the dystrophin gene. Defects in the dystrophin gene in 
DMD, are homologous to that found in mdx mice, and result in profound muscle damage, 
inflammation and weakness in diaphragm and limb muscles. Dystrophin, a scaffolding 
protein located in the sarcolemmal cytoskeleton, helps cells to maintain their structural 
integrity and associates with critical cell signaling molecules that regulate cell growth 
and repair (e.g., nNOS).  
While the contributing mechanisms leading to DMD-induced degenerative 
muscle function and damage are multi-factorial, elevated oxidative stress has been 
proposed as a central mechanism. In contrast, antioxidants can attenuate muscle damage 
as well as improve contractile function in dystrophin-deficient muscles. However, it is 
unknown if oxidative stress is a causal factor in dystrophin-deficient diaphragm muscle 
pathology and specifically targeted antioxidant (e.g., EUK-134) treated early in the 
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course of the disease (3-4 weeks) can modulate oxidative stress, functional damage and 
weakness in mdx diaphragm.  
Therefore, the purpose of this study was to determine the effects of 
catalase/superoxide dismutase mimetic EUK-134 on damage, inflammation, and 
contractile function of the diaphragm muscle in mdx mice. We hypothesized that (a) 
EUK-134 would attenuate muscle damage and oxidative stress in mdx diaphragm, (b) 
EUK-134 would reduce inflammatory cells and an important transcription factor 
including nuclear factor-kappaB (NF-κB) in mdx diaphragm and (c) EUK-134 would 
restore proteins that attach to dystrophin such as nNOS and cytoskeletal proteins back to 
sarcolemmal region and improve muscle contractility in mdx diaphragm. 
C57BL/10ScSn wild type and mdx mice were given EUK-134 (30mg/kg, i.p., 
injection) beginning at 20 days of age for 8 days. The mice were euthanized and the 
diaphragm muscle was harvested at 4 weeks of age, the time of peak inflammation, and 
analyzed to measure myofiber inflammation, NF-κB activation, cytoskeletal proteins and 
oxidative stress markers using Western immunoblotting, ELISA, immunofluoresence, 
and immunohistochemistry. We found that EUK-134 ameliorated muscle damage and 
oxidative stress in mdx diaphragm. EUK-134 protected against inflammation by 
decreasing NF-κB activation in the nucleosome fraction of mdx diaphragm. Further, 
EUK-134 partially rescued nNOS and α-1 syntrophin back to sarcolemmal membranes 
and recovered force generation even in acute application in vitro in mdx diaphragm.   
These results are the first to demonstrate a causal relationship between oxidative 
stress and pathology caused by dystrophin-deficient diaphragm muscle. Moreover, the 
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data indicate that EUK-134 has a protective effect against muscle damage, inflammation, 
and contractility in mdx diaphragm. We believe that the results from our investigation 
will provide clinical significance, as we expect to elucidate mechanisms by which 
oxidative stress contribute to tissue damage and weakness in dystrophic diaphragm. 
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CHAPTER I 
INTRODUCTION 
 
Duchenne muscular dystrophy (DMD) is a severe genetically determined muscle-
wasting disorder characterized by gene mutations or deletions of the structural protein, 
dystrophin. Genetic defect in DMD, which is homologous to that found in mdx mice, has 
been related to tissue damage, weakness, inflammation, apoptosis, necrosis, and fibrosis in 
respiratory and locomotor muscles. Mounting evidence indicates that oxidative stress, 
inflammation, cytoskeletal disruption, mitochondrial dysfunction, and impaired stress 
response are important contributors to degenerative tissue function and damage in mdx mice.  
Elevated oxidative stress has been proposed as a central mechanism to DMD-
induced muscle damage and dysfunction (Appendix 1). In contrast, antioxidants can 
attenuate muscle damage as well as improve contractile function in dystrophin-deficient 
muscles. However, it is unknown if oxidative stress is a causal factor in dystrophin-
deficient diaphragm muscle pathology and specifically targeted antioxidant (e.g., EUK-
134) treated early in the course of the disease (3-4 weeks) can modulate oxidative stress, 
functional damage and weakness in mdx diaphragm.  
Therefore, we examine our hypothesis by pursuing the following specific aims. 
(i) identify the role of oxidative stress on functional and morphological properties in mdx 
diaphragm (ii) identify the role of oxidative stress on inflammatory signaling pathways 
                                                 
  This dissertation follows the style of Journal of Applied Physiology. 
 2
in mdx diaphragm (iii) identify the role of oxidative stress on dislocation of nNOS, 
dystrophin-associated scaffolding proteins and contractile properties in mdx diaphragm. 
 To accomplish the above specific aims, we hypothesized that (i) EUK-134 will 
reduce oxidative stress and muscle damage in mdx diaphragm (ii) EUK-134 will reduce 
inflammatory cells and NF-κB activation in mdx diaphragm (iii) EUK-134 will restore 
nNOS and α-1 syntrophin back to sarcolemmal region and improve contractile function 
in mdx diaphragm.  
 
DMD and dystrophin  
Duchenne muscular dystrophy (DMD) is the most common and devastating type 
of human muscular dystrophy, first described in the mid-1800s by Meryon and 
Duchenne. DMD is an intrinsic X-linked recessive disorder in dystrophin gene and 
affects approximately 1 in every 3500 males. Two-thirds of genetic mutations in the 
dystrophin gene are caused by deletions and duplications, and remaining one-third has 
point mutations or insertions (30, 97, 132). Genetic defects in DMD result in profound 
muscle damage, inflammation, weakness and fibrosis in both respiratory and locomotor 
muscles. The symptoms of DMD appear by 3 years causing walking difficulties and 
balance problems and by 12 years are typically no longer able to breathe or walk on their 
own (48). The progressive, rapid, and severe deterioration in muscles eventually leads to 
premature death in their late teens to early twenties mainly due to respiratory and 
cardiovascular failure (48, 170).  
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One of the hallmarks of the muscular dystrophies initiated by a mutation of 
single gene, dystrophin is that the severity and progress of pathology differ that range 
from the most mild and slow to the most severe and fast. In human, dystrophin 
deficiency leads to the most severe and fast muscle disease, Duchenne muscular 
dystrophy (DMD), whereas reductions or truncations of dystrophin causes a milder and 
slow muscle disease, Becker muscular dystrophy (BMD). 
The mdx mouse is most widely used animal model for DMD in human that 
carries a naturally occurring point mutation at position 3185 of dystrophin gene (132). 
Although dystrophin is absent in both mdx mice and DMD patients the phenotype of 
mdx mice is much less severe than that seen with DMD in humans. Moreover, the 
hindlimb muscles in mdx mice are different histologically from diaphragm muscle, 
which more closely resembles DMD muscles. The dystrophin-deficient limb muscles in 
mdx mice undergo a series of degeneration, necrosis and inflammation starting at 2-3 
postnatal weeks and persisting throughout the lifespan of animals. Then most of the 
locomotor muscles are efficiently regenerated and only undergo mild weakness in adult 
mice (111). However, the diaphragm muscle in dystrophin-deficient mdx mice initially 
display a regeneration process that does not compensate for massive degeneration and 
fails to restore muscle structure and function which are similarly seen in DMD patients 
(140). Therefore, diaphragm in mdx mice can be more valuable for studying the human 
DMD than other muscles. 
Another different characteristic between DMD humans and mdx mice is the 
average lifespan. Dystrophin-deficient mdx mice live a relatively longer period of time 
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than DMD patients whose average lifespan is shortened by 60 to 70%. However, the 
lifespan in mdx mice is reduced moderately in both male and female compared with 
wild-type mice. The mdx mice rarely live past two years, while wild-type mice live two 
and a half to three years. Recently, Chamberlain et al (27) demonstrated that lifespan 
reduction for male (-19%) and female (-17%) occur in mdx mice compared with wild 
type mice. 
Dystrophin is a large (427kD) protein and a central component of the 
sarcolemmal dystrophin-associated protein complex (DAPC). Genetic mutations in 
dystrophin or DAPC proteins results in a variety of muscular dystrophy, which are often 
associated with defects in sarcolemmal membrane. Dystrophin consists of an amino(N)-
terminal actin-binding domain, a central rod-like domain, and cystein-rich carboxy(C)-
terminal domain that allows assembly of the DAPC (47). Dystrophin binds to 
cytoplasmic γ-actin at its amino terminus and regions along the spectrin-repeated rod 
domain and to transmembrane protein β-dystroglycan at its carboxyl terminus. The N-
terminal and extracellular portion of β-dystroglycan associate with α-dystroglycan and 
basement membrane (114).  
In muscles, dystrophin plays an important role in maintaining sarcolemmal 
integrity by bridging the subsarcolemmal cytoskeleton, the sarcolemma, and the 
extracellular matrix (ECM), and transmiting force laterally across the sarcolemma to the 
ECM (89). DMD compromises the mechanical resilience of the cytoskeleton and cellular 
membrane to repeated mechanical strain (116). The muscles in DMD patients display a 
lower threshold for material fatigue injury with repeated stretch or eccentric contractions 
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(32, 161). The limb muscle of DMD that is absent in dystrophin is abnormally 
susceptible to contraction-induced cytoskeletal disruption, immune cell invasion and 
muscle wasting (42, 96, 116, 128), resulting in massive inflammation, apoptosis, 
necrosis, damage and atrophy (136, 146), along with an increase in connective tissue, 
and thus stiffness and internal work (59). Muscle wasting with DMD is primarily a 
function of muscle protein breakdown and cell loss, and not a result of impaired protein 
production (8).  
In addition to its mechanical and structural role, dystrophin also regulates 
signaling molecules, such as neuronal nitric oxide (nNOS), Grb2, and others to the 
sarcolemma, which are involved in protein turnover, growth, blood flow and adhesion 
proteins (79, 116).  
  
DMD and dystrophin-associated protein complex (DAPC) 
Dystrophin deficiency in DMD humans and mdx mice leads to a marked 
reduction of other dystrophin-associated protein sarcolemmal and subsarcolemmal 
proteins, called dystrophin-associated protein complex (DAPC). The DAPC plays a 
major role in linking the actin cytoskeleton to the extracellular matrix, stabilizing the 
sarcolemma during contraction and relaxation, transmitting force generated in the 
muscle sarcomeres to extracellular matrix, and integrating cell signaling in response to 
mechanical strain (79).  
Based on their biochemical properties, the DAPC can be subdivided into three 
subcomplexes as follows: the dystroglycan complex (DGC), the sarcoglycan-sarcospan 
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complex (the sarcoglycan complex associated with sarcospan), and the cytoplasmic 
complex (e.g., dystrophin, syntrophin, and dystrobrevin) (34, 147).   
Dystroglycan complex (DGC) constitutes an essential core of the DAPC as it 
establishes a transmembrane link between laminins and dystrophin (34). DGC consists 
of an α-dystroglycan binding to lamin-2 and a β-dystroglycan binding to α-dystroglycan 
as well as the C-terminal of dystrophin and so complete the connection from the inside 
to the outside of the cell. Targeted deletion of dystroglycan in mice results in embryonic 
death than progressive muscle damage, indicating that dystroglycan is indispensable for 
early embryonic development (168). 
Sarcoglycan proteins are integral membrane glycoproteins which associate with 
β-dystroglycan (89). There are five sarcoglycan proteins: α-sarcoglycan(50kDa, also 
called adhalin), β-sarcoglycan(43kDa), γ-sarcoglycan(35kDa), δ-sarcoglycan(35kDa), 
and ε-sarcoglycan(50kDa) (47). α-dystrobrevin and γ-sarcoglycan can interact directly 
and genetic mutation or deletion for α-, β-, γ-, and δ-sarcoglycan results in various types 
of limb-girdle muscular dystrophy (LGMD) types 2D, 2E, 2C, and 2F, indicating that 
sarcoglycan loss is the major mediator of membrane frailty and muscle disease (23, 33, 
43, 55, 140). Sarcoglycan proteins participate in protein interaction between the 
membrane and the matrix (160).  
Each α-sarcoglycan and β-sarcoglycan binds to a small biglycan in their 
extracellular portions. Biglycans are proteoglycan aggregates that play an important role 
in organizing the intracellular components of the DAPC, including the syntrophins, 
dystrobrevins by way of its interaction with sarcoglycan-sarcospan complex (160). 
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Sarcospan is a 25kD membrane protein predominantly seen in skeletal and cardiac 
muscle sarcolemmal membrane. Although the amount of sarcospan is reduced in DMD 
muscle, lack of sarcospan does not develop muscular dystrophy (47).  
The cytoplasmic complex of DAPC includes the syntrophins, dystrobrevins, 
nNOS, and dystrophin. Syntrophins are a family of scaffolding proteins that contain 
multiple protein interaction motifs. In human and mouse, five highly conserved but 
distinct syntrophin isoforms, α1-, β1-, β2-, γ1-, and γ2-syntrophin, have been described 
(167). Each syntrophin isoform consists of two pleckstrin homology domains (PH1 and 
PH2), an N-terminal PSD/Discs-large/ZO-1 homologous (PDZ) domin, and a short 
syntrophin unique (SU) COOH-terminal domain (80). Syntrophins bind directly to 
dystrophin, utrophin, and dystrobrevin and its interaction is mediated by the PH2 domain 
and SU COOH-terminal domain together (2). The PDZ domain of α1-syntrophin binds 
to voltage-gated sodium channels and neuronal nitric oxide synthase (nNOS). Thus, α1-
syntrophin is of major importance for recruiting and anchoring nNOS to the sarcolemma 
via dystrophin. α1-Syntrophin, localized on the sarcolemma and neuromuscular junction 
with dystrophin, is predominantly expressed in skeletal and cardiac muscle whereas β1 
and β2-syntrophin, primarily restricted to the neuromuscular junction, are expressed in 
wide variety of tissues (73, 112). It has been demonstrated that lack of syntrophin leads 
selective loss of nNOS but not develop muscular dystrophy (102).  
Dystrobrevins are components of DAPC and form an intracellular peripheral 
subcomplex thought to serve as a scaffold for signaling proteins (52). The two 
dystrobrevin isoforms α and β, are encoded by different genes. α-Dystrobrevin, localized 
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to the sarcolemma and neuromuscular junction, is the predominant isoform in skeletal 
muscle (71). β-Dystrobrevin is expressed in brain, liver, lung and kidney, but not in 
skeletal muscle (66). α-Dystrobrevin binds both dystrophin and syntrophin. Lack of 
dystrobrevins exhibits milder muscle pathology than humans with DMD (52, 71). 
Nitric oxide (NO), generated from L-arginine by nitric oxide synthase (NOS), is 
an important and highly versatile signaling modulator involved in regulation of 
numerous cellular functions including tissue injury, repair and disease (31, 74). In 
mammals, three isoforms of NOS, neuronal (nNOS, NOS1), inducible (iNOS, NOS2), 
endothelial (eNOS, NOS3), have been reported to be expressed under normal conditions. 
Neuronal nitric oxide synthase (nNOS) is a predominant isoform expressed in muscle, 
where it is co-localized at the sarcolemma within the DAPC (19, 158). nNOS interacts 
directly with α1-Syntrophin, which is associated with dystrophin (158). In the absence of 
dystrophin of DMD humans and mdx mice, nNOS is absent from sarcolemma and 
partially accumulates in the cytosol where it maintains some of its enzymatic activity (20, 
28). Dislocation of nNOS from the dystroglycan complex could (a) increase NAD(P)H 
oxidase activity, (b) increase inflammation, (c) increase protein degradation via 
activation of ubiquitin ligases, and (d) impair satellite cell activation (107, 153). 
Reduction in nNOS coupled with increase susceptibility to material fatigue injury could 
exacerbate damage and inflammation (153). However, the loss of nNOS from the 
sarcolemma is not sufficient to make a dystrophic phenotype but plays a contributory 
role in boosting tissue damage in response to dystrophic loss (118).  
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DMD and inflammation  
Inflammation in muscle damage and repair 
Inflammation is one of the first responses of the immune system which is 
initiated when tissues are damaged through a variety of mechanisms, including trauma, 
hypoxia, infections, toxins, heat or other causes (149). Various types of tissue damage 
results in the initiation of regeneration and repair response which is a coordinate process 
accompanied by the proliferation and differentiation of muscle progenitor cells also 
referred to as satellite cells. The process of muscle regeneration and repair is completed 
by a series of degeneration, inflammation, regeneration, and fibrosis (68, 70, 148). 
Inflammation can be divided into two phases: acute and chronic. Acute 
inflammation is regarded as a transient, beneficial response to tissue injury. Hallmarks of 
acute inflammation is increased blood flow with vasodilation and vascular permeability 
changes along with the accumulation of fluid, leukocytes, and inflammatory mediators 
such as neutrophils, monocytes and macrophages (50, 148). Inflammatory response is 
apparent in the muscle within 1 to 24 hour of damage. However, in various types of 
acute muscle damage, the high concentration of inflammatory cells persists for several 
days following damage, after which they gradually return to normal concentration over a 
period of several days to weeks (151).   
Chronic inflammation, a persistent phenomenon that progress from acute 
inflammation if the injurious agent exists, is characterized by infiltration of 
inflammatory cells such as macrophages, lymphocytes and plasma cells, leading to tissue 
damage (94).  A rapid and sequential invasion of inflammatory cell populations can 
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persist for days to weeks until tissue repair, regeneration, and growth occur (149). It has 
been also demonstrated that dystrophin-deficient pathology is related to chronic 
inflammation (63).  
Inflammatory response is a compelling candidate and plays an important role in 
mediating myofiber damage after ischemia-reperfusion, trauma, exposure to toxins, or 
inheritable muscle pathologies including muscular dystrophy (144, 150). Inflammation 
also has a beneficial effect promoting muscle repair and regeneration after injury as well 
as detrimental effect disrupting muscle homeostasis. The dual role of inflammation is 
overall influenced by the magnitude of the response, the previous history of muscle use, 
and injury-specific interactions between muscle and the inflammatory cells (149). 
However, the interactions between muscle and inflammation are highly complex and not 
seem to be wholly beneficial for muscle (149).  
A dominant inflammatory response against modified muscle use and damage 
includes massive infiltration by neutrophils (6, 21, 144, 149, 151, 156). Neutrophils are 
rapid and early respondent inflammatory cells to appear in the damaged site since they 
migrate into the muscle from the vasculature (151). The main function of neutrophils is 
to destroy damaged tissue via phagocytosis and degrade damaged area by proteases 
either intrinsic to muscle or proteolytic systems introduced by phagocytic cell 
infiltrations (156). Phagocytic and proteolytic activation of neutrophils in response to 
tissue damage is dominated by the respiratory burst and degranulation, in which 
neutrophils rapidly release free radicals such as superoxide (O2•–), are potentially 
cytotoxic and may cause muscle damage (156). 
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Several observations have provided that neutrophil-mediated damage to muscle 
is related to defects in muscle contractility as well as oxidative stress production. This 
has been most convincingly demonstrated in muscle using ischemia reperfusion (I/R) 
model. Neutrophil depletion prior to I/R showed significant less decrease in peak 
isometric tension than occurred in non-depleted animals (159) and neutrophil-mediated 
muscle damage has been largely prevented by administration of superoxide dismutase 
(SOD) (106, 134). Another important finding that neutrophils cause muscle damage 
through an O2•– and hypochlorous acid-mediated mechanisms includes the rodent 
hindlimb muscle unloading/reloading models (107). 
Macrophages are involved in muscle damage and repair. Macrophages are more 
predominant during the later stages of inflammation after damage. However, the roles in 
influencing the course of muscle injury and repair are more complicate than the role of 
neutrophils, since macrophages are activated by diverse growth factors (e.g., fibroblast 
growth factor [bFGF], VEGF), chemokines (e.g., MCPs ), cytokines (e.g., tumor 
necrosis factor-α[TNF-α], interleukins[ILs], interferons[IFNs]) as well as free radicals 
(149). Macrophages in muscle can be divided into two distinct populations: Classically 
activated macrophages (also called type I+, EDI+, Ia macrophages) and alternatively 
activated macrophages (also called type II+, EDII+, dMHC macrophages) (11, 21, 65). 
Type I+ macrophages are associated with necrosis in muscle injury, whereas type II+ 
macrophages are associated with muscle regeneration (139). Therefore, the localization 
of type I+ macrophages inside necrotic myofibers indicates that these cells function as 
phagocytes, whereas type II+ macrophages function as non-phagocytic regenerative role 
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in muscle. St. Pierre et al (139) demonstrated that type I+ macrophages invaded necrotic 
fiber in 2-day reloaded muscles and type II+ macrophages were increased significantly 
and not infiltrated to necrotic muscle fiber in 4- and 7-days of reloading muscle. 
Nguyen and Tidball (106) demonstrated cytotolytic capacity of macrophages has 
been increased in muscle cells by nitric oxide-dependant mechanisms in which increased 
NO-medicated toxicity by macrophages promotes muscle damage. Several observations 
indicate that macrophages play an important role in promoting muscle repair and 
remodeling after injury and modified use. Part of the contribution of macrophages in 
repair process is due to the removal of debris via phagocytosis although it is not known 
if removal of debris is required for repair after injury (149). 
 
Inflammation in dystrophin-deficient muscles 
Muscle degeneration, necrosis, inflammation, and fibrosis are prominent 
pathological features of muscular dystrophy in DMD humans and mdx mice (84). 
Mounting evidence indicate that inflammatory processes are highly integrated into the 
pathologies of dystrophin-deficient muscle (63, 136). It has been suggested that the 
complex pathology of human DMD and mdx mice due to the disruption of structural 
protein, dystrophin leads to the immune cell infiltrations in response to the damage and 
degeneration (64, 135). 
Inflammation of dystrophic-deficient muscle involves a specific invasion of 
autoreactive immune cells into damaged sites (136). The major constituents of the 
inflammatory cell population of dystrophin-deficient muscle are macrophages, T-cells, 
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and eosinophils (135). Macrophages, CD4+ cells (helper lymphocytes) and CD8+ cells 
(cytotoxic lymphocytes), commonly existing in perimysial and endomysial sites of 
muscles, are involved in muscle degeneration, necrosis, apopotosis, and fibrosis in mdx 
mice (104, 137). The depletion of macrophages, CD4+ and CD8+ cells or impairment of 
cytotoxicity by the removal of perforin ameliorated muscle histopathology and increased 
muscle repair and regeneration in 3-4 week old mdx mice (135, 137, 164). Moreover, 
depletion of T-cells in mdx mice reduces other inflammatory cells such as eosinophils, 
which have the capacity to promote cell membrane lysis and cell deaths by surrounding 
the degenerative muscle fibers (24, 163) . Morrison et al (104) suggest that T-cells play a 
role in the onset of the fibrosis which deteriorates the ability of dystrophic muscle to 
regenerate. 
Inflammation is an early event in the pathological feature in dystrophin-deficient 
mdx mice and DMD humans. Inflammation and muscle cell death is first apparent at 3-4 
weeks of age, with regenerative muscle replacing pathological muscle by 14 weeks of 
age in mdx mice (136). In human DMD, inflammation display mild, histotologically 
discernible at birth but remain no symptomatic until 3-4 years of age (110, 136). The 
mechanisms by which inflammatory cells promote the dystrophic pathology remain 
unknown. However, NF-κB activation, oxidative stress and cytokines appear to have an 
integrative effect in the progression of muscular dystrophy (83, 113).  
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NF-κB in dystrophin-deficient muscles 
NF-κB is a major transcription factor which regulates a variety of gene 
expression involved in cell survival, proliferation, inflammation and apoptosis (76, 113). 
In mammals, NF-κB family consists of 5 subunit proteins: p65 (Rel-A), Rel-B, c-Rel, 
p50, and p52 (1). In normal condition, NF-κB is maintained in an inactive form in the 
cytosol through binding of the I-kappaB (IκB). Typical IκB family members consist of 
IκBα, IκBβ, and IκBε. IκB family contains a nuclear export sequence (NES) which 
retains NF-κB heterodimer (p65 and p50) in the cytosol as an inactive complex. NF-κB 
transcriptional activity is inhibited by function of IκB which masks one of the subunit’s 
nuclear localization sequence (NLS) and inhibits DNA binding (62). NF-κB activation 
and IκB degradation are tightly regulated through inhibitory kinase complex known as 
IκB kinase (IKK). IKK consists of two catalytic subunits (IKKα, IKKβ) and a regulatory 
subunit (IKKγ/NEMO) (1). NF-κB can be activated in response to different stimuli such 
as proinflammatory cytokines (e.g., TNF-α, IL1-β) (56) and oxidative stress (93, 157). 
Such stimulatory signals result in IKK-mediated phosphorylation and proteolytic 
degradation of IκB, leading its dissociation from NF-κB complex with translocation 
heterodimer p50/p65 to nucleus Translocated NF-κB p50/p65 subunit binds to target 
DNA and activates transcription, which include a variety of cellular gene involved in 
inflammatory, immune, and proliferative response (145).  
Skeletal muscle specific NF-κB activation is not an inherent consequence in 
dystrophin-deficient muscles. Recent evidence suggested that NF-κB activity has been 
diminished during first 1.5 weeks of postnatal muscle development of mdx mice (1). However, 
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NF-κB activity in mdx mice subsequently become reactivated and persisted at 3 weeks of 
age (1). Mounting evidence indicates that elevated nuclear NF-κB activation is a key 
feature and plays an important role in the process of muscle pathology in both DMD in 
humans (103) and mdx mice (1, 82, 103).  
Monici et al (103) have reported that NF-κB immunoreactivity was increased in 
the cytoplasm of all regenerating fibers and 20-40% of necrotic fibers in DMD patients. 
Kumar et al (82) have demonstrated that NF-κB DNA binding activity and the 
expression of NF-κB-regulated inflammatory cytokines such as TNF-α and IL-1β was 
significantly higher in mdx diaphragm, even in 15-day-old compared with controls and 
IκBα protein levels were also lower in mdx diaphragm. Acharyya et al (1) also have 
reported that NF-κB DNA binding activity was found to be higher in mdx diaphragm, 
tibialis anterior (TA) and gastrocnemius muscle. Specifically, immunohistochemical 
analysis of dystrophin-deficient DMD and mdx mice muscle have showed that NF-κB 
p65 subunit has been localized to infiltrating immune cells (113). The protein levels of 
NF-κB p65 in nuclear fraction were much greater for mdx skeletal muscle than for wild-
type muscle (165). The supershift analysis of NF-κB/DNA complex and genetic 
manipulation have revealed that NF-κB subunit p50 and p65 proteins are activated in 
immune cells and myofibers of mdx mice and p65 is transcriptionally more active 
subunit contributing to dystrophin-deficient pathology (1, 82).  
Involvement of dysregulated NF-κB in dystrophin deficient muscle makes NF-
κB an attractive target to explore for the potential to approach pathological treatment in a 
comprehensive manner. It has been demonstrated that genetic manipulation (1) or 
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pharmacological blockade (25, 100, 109) of NF-κB can alleviate the severity of the 
pathological phenotype in mdx mice. Acharyya et al (1) have reported that genetic 
deletion of NF-κB subunit p65 and IKKβ promote muscle regeneration and reduce 
pathologic phenotype including inflammation in mdx muscle. Carlson et al (25) have 
suggested that treatment with pyrrolidine dithiocarbamate (PDTC), an agent which 
inhibits NF-κB nuclear activation by cytosolic stabilization of IκB-α, significantly 
improve the survival of muscle fibers and resting potentials (RPs) in passively stretched 
dystrophic skeletal muscle. Messina et al (100) also showed the beneficial effects of 
PDTC on biochemical, functional and morphological parameters in mdx muscle, 
resulting in decreased necrosis, and enhanced muscle regeneration and contractile 
function. The administration of curcumin, a plant-based NF-κB inhibitor derived from 
the spice turmeric used in curry, has been reported to attenuate NF-κB activation and 
dystrophic pathology in mdx skeletal muscle (109). However, Durham et al (46) have 
failed to reduce NF-κB activation and improve contractile function with curcumin in 
diaphragm and skeletal muscle. Methodological discrepancy can account for the 
inconsistent outcome. Recently, the use of NBD (NEMO-binding domain) peptide, a more 
specific non-toxic IKK inhibitor has shown to be a promising candidate for treatment of 
mdx pathology, resulting in improved muscle contractile function and reduced macrophage 
accumulation and myofiber necrosis in dystrophin-deficient muscle (1).  
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DMD and oxidative stress 
Muscle damage and weakness with DMD are proposed to result from repetitive, 
material fatigue injury and inflammation (32, 117, 136, 161). Mounting evidence 
suggests that inflammatory signaling, including nuclear factor-kappaB (NF-κB), 
cytokine (TNF-α, IL-1β) pathways, may be linked to increased oxidative stress (54, 
153). A potential primary mechanism that may link material fatigue injury and 
inflammation with clinical symptoms of diaphragm dysfunction in DMD patients is 
proposed to be oxidative stress (49, 119, 125, 153). 
Oxidative stress is the result of (a) increased reactive oxygen species (ROS) and 
reactive nitrogen species (RNS) (b) decreased, insufficient, or imbalanced antioxidant 
enzymes and stress proteins (e.g., heat shock proteins, IGF-1). An imbalance between 
ROS/RNS production and antioxidant defense mechanisms lead to increased ROS/RNS-
induced cellular dysfunction, damage and tissue degeneration (117).  
The possibility that oxidative stress contributes to muscle pathology in DMD has 
been proposed first by Binder et al (14) who noted the similarities to muscle pathology 
that occurred in tocopherol (e.g., vitamin E) deficiency, which directly increase in free 
radicals and oxidative damage. Subsequently, Mendell et al (98) have suggested that 
ischemia-reperfusion injury to muscle produces oxidative lesions and damage with 
pathological characteristics which is very similar to those of the muscular dystrophy.  
 The markers of oxidative stress have been extensively investigated in DMD 
humans and mdx mice. Byproducts of lipid peroxidation (e.g., TBARS, expired pentane), 
DNA and protein oxidation are elevated with DMD in humans and mdx mice (60, 61, 72, 
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115, 125). Nakae et al (105) have suggested that lipofuscin, a biomarker of oxidative 
injury, formed by the oxidative degradation of celluar macromolecules by oxygen-
derived free radicals and redox-active metal ions has been accumulated early phases in 
dystrophin-deficient DMD humans (~2 years) and mdx mice (~4 weeks).  
In addition, the dystrophin-deficient muscle is also more susceptible to oxidative 
damage than normal muscle (40, 41, 119).  Rando et al (119) showed that dystrophin-
deficient myotubes are more susceptible to oxidative stress-induced damage compared 
with normal cells. Disatnik et al (40) reported that the susceptibility of the cell 
populations to oxidative stress is increased with severity of the phenotype in the 
respective mdx and mdx-transgenic strain. Rando (118) has proposed a “two-hit” 
hypothesis where the combination of oxidative stress with disturbances in the 
dystrophin-glycoprotein complex (DCG) leads to pathology with DMD. However, only 
more recently has the tie between oxidative stress and pathology in muscles with DMD 
moved beyond association (138, 153, 165, 166).  
Various sources of ROS in respiratory and locomotor muscles with DMD 
include the inflammatory cells (e.g., myeloperoxidase), NAD(P)H oxidase (NOX), 
xanthine-xanthine oxidase, mitochondria, and decoupling of inducible nitric oxide 
synthase (iNOS) (3, 10, 138, 165, 166). Furthermore, oxidative stress may also be 
exacerbated in muscle wasting disease by insufficient stress response including heat 
shock proteins and IGF-1 (17).  
In addition, downregulation and dislocation of nNOS from the DAPC may also 
elevate oxidative stress and lead to muscle damage (107, 131, 152, 164). nNOS known 
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as µNOS in skeletal muscle appears to be attached to DAPC scaffolding proteins 
dystrophin and dystrobrevin via a- and ß-syntrophin (116). DMD-induced impairment of 
mitochondrial function can lead to oxidative stress, apoptosis, and necrosis (12).  
 
DMD and therapeutics  
Muscle necrosis, inflammation, and fibrosis are prominent pathological features 
of dystrophin-deficient DMD humans and mdx mice. These pathological changes lead to 
progressive muscle damage and weakness in dystrophin-deficient muscles. One of 
important therapeutic approaches to improve muscle function and dystrophin-deficient 
phenotype therefore is to ameliorate these pathological changes. Many therapeutic trials 
have been treated with the purpose of ameliorating and curing the muscular dystrophy. 
However, there has been no successful treatment for the diseases. 
Gene therapy or cell therapy to replace the absence of dystrophin are promising 
but not yet applicable. The treatment of corticosteroids such as prednisone and 
deflazacort offers partial benefit by reducing oxidative damage and inflammation, but 
has some side effect profile including impaired growth and maturation, weight gain, 
osteopenia, immunosuppression, and susceptibility to infection (26, 133). NF-κB 
inhibitor curcumin (109) and pyrrolidine dithiocabamate (PDTC) (100) might attenuate 
muscle degeneration and enhances muscle regeneration and function in mdx mice, 
suggesting a beneficial effect of NF-κB blockade on muscle repair. Imatinib, an anti-
inflammatory and anti-fibrotic agent, markedly ameliorated muscle necrosis, 
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inflammation and fibrosis via downregulating platelet-derived growth factor (PDGF) and 
c-abl signaling pathways and significantly improved muscle function in mdx mice (67). 
Prevention of oxidative damage by providing different antioxidant in dystrophin-
deficient muscles has positive effect. Antioxidant green tea extract (22), low-iron diet 
(16) resulted in a significant reduction of necrosis in dystrophin-deficient mdx mice, but 
no similar benefits were not demonstrated in DMD humans (7, 51, 126, 141). These 
studies were performed on some patients already undergoing muscle pathologies, which 
may have limited their effectiveness. In addition, depending on the types of ROS 
produced by dystrophic muscles, some antioxidants may be more effective than others in 
preventing oxidative stress-induced muscle damage and weakness in dystrophin-
deficient muscles. Therefore, even if oxidative stress is in indeed the primary 
pathological mechanism leading to muscle damage and weakness, effective treatment 
will need to be targeted to the specific deficit in antioxidant defense and initiated early in 
the course of the disease (117).  
NAD(P)H oxidase is a source of oxidative stress localized in cell membrane and 
inflammatory cells (107). Importantly, elevations of NAD(P)H oxidase have been 
identified in the heart and muscles of mdx mice that indeed may play a significant role in 
muscle damage, weakness, and wasting (138, 166). Recently, a 6 week treatment of N-
acetylcysteine (NAC), a NAD(P)H oxidase inhibitor, was found to protect against 
damage, incidence of internal nuclei, and weakness in the EDL muscle of 8 week old 
mdx mice (165). In addition, NAC also increased protein levels of the ß-dystroglycan 
and utrophin while decreased caveolin-3 proteins. NAC also reduced dihydroethidine 
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oxidation (DHE, a marker of superoxide generation) and protein expression of the p65 
subunit of NF-κB (165), an inflammatory transcription factor that also stimulates 
proteolysis via the ubiquitin pathway. NAC treatment also reduced macrophage invasion 
and collagen accumulation in the hearts of mdx mice (166). 
Given the emerging promise of oxidative damage preceding pathological changes 
and antioxidant therapy attenuating muscle pathology and weakness with DMD, 
increasing data implicate the importance of hydrogen peroxide and superoxide in muscle 
wasting models (5, 87, 165). In dystrophin-deficient muscle, xanthine-xanthine oxidase 
system and NAD(P)H oxidase may contribute to the generation of superoxide, which, in 
turn, is dismutated to hydrogen peroxide by superoxide dismutase (10, 165). EUK-134 is 
a part of salen-manganese family compounds, which quench superoxide anion and 
hydrogen peroxide, developed by Eukaryon (Appendix 2). It has been demonstrated that 
EUK compounds protect against oxidative damage, radiation, and may increase lifespan 
(9, 18, 39, 88, 127). Therefore, administration of EUK-134 on dystrophin-deficient mdx 
muscles can be a potential target for therapeutics. However, the efficacy to modulate 
oxidative stress, functional damage and weakness in the mdx diaphragm is unknown. 
The diaphragm muscle suffers from significant fibrosis, damage, and weakness 
with DMD, and is also susceptible to oxidative stress (13, 154). Oxidant production may 
be higher in the mdx diaphragm than limb muscles, which could contribute to more 
profound fibrosis, weakness, and fatigue in that muscle (59, 142). In addition, the 
diaphragm muscle in mdx genetic mouse model experiences muscle damage, disease 
progression, and gene expression profiles that are more similar to human DMD 
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pathology than observed in limb muscles, which tend to recover or adapt (153, 154). 
Therefore, the study of the mechanisms by which oxidative stress causes pathology in 
mdx diaphragm, and development and testing of targeted, antioxidant therapeutics is 
vital in translation to human health and pathology with DMD. 
 
 
 23
CHAPTER II 
METHODS 
 
Animals 
We used C57BL/10ScSn-mdx/J dystrophic (mdx) mice and wild-type 
C57BL/10ScSn mice as controls. C57BL mice are one of the most widely used inbred 
strains and used as a human DMD in rodents (155). Mice were purchased from Jackson 
Laboratory and cared for at the Comparative Biology Laboratory facility at Texas A&M 
University complied with the code of conduct for University Laboratory Animal Care 
Committee (ULACC) standards. Mice were housed in a temperature-controlled (20ºC±2 
ºC) environment with a 12-h light-dark cycle, and free access to water and mouse chow 
(4% standard powder) provided ad libitum after weaning at 18 days of age. 
 
Experimental design 
Twenty-day old mdx mice and C57BL wild type controls were assigned to the 
following groups: wild-type controls + saline (WS, n=7), wild-type controls + EUK-134 
(WE, n=7), mdx mice + saline (MS, n=7), mdx mice + EUK-134 (ME, n=7). EUK-134 
(30mg/kg, 0.05cc-0.2cc, i.p) were injected daily beginning at 20 days of age for 8 days. 
At 28 days of age, mice were euthanized by Na pentobarbital (120mg/kg). To avoid last 
treatment effect, mice were sacrificed 24 h after the last treatment of EUK-134. 
Diaphragm was then quickly extracted, weighted and snap frozen in isopentane cooled in 
liquid nitrogen and stored at -80°C until analyses. 
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Homogenization procedure 
Diaphragm was minced into fine pieces, weighted and suspended (26:1 v/w) in 
ice-cold complete lysis buffer A (pH=7.4) comprised of the following: 10 mM HEPES, 
350 mM NaCl, 20 % glycerol, 1% Igepal-CA630, 1 mM MgCl2, 0.1 mM DTT, 0.1 mM 
EGTA, and protease inhibitor cocktail (Roche Applied Science). Each diaphragm was 
homogenized in a Dounce ground glass homogenizer (Bellco Biotechnology; Vineland, 
NJ) at 4°C. The homogenates were first centrifuged (4°C) for 10 min at 3,000g, and 
supernatant was separated from the pellet. The supernatant was centrifuged (4°C) for 10 
min at 10,000g to get soluble fraction. Nucleosome fraction was isolated using this pellet 
resuspended by complete lysis buffer B containing the following: 20 mM HEPES, 350 
mM NaCl, 10 % glycerol, 1 mM MgCl2, 0.1 mM DTT, and protease inhibitor cocktail 
(Roche Applied Science) and centrifuged again for 30 min at 12,000g. The supernatant 
of this fraction contains nuclei. Protein concentration was measured using BCA protein 
assay reagent kit (Pierce) at 562 nm absorbance with spectrophotometer. 
 
Measurement of citrate synthase activity 
Citrate synthase activity in the diaphragm was measured as a marker of oxidative 
capacity and indicative of mitochondrial density and function as described previously 
(78). Briefly, citrate synthase cocktail including DTNB (dithio-bis 2-nitrobenzoic acid; 
0.1 mM), Triton X-100 (0.07%), and Acetyl CoA (0.1 mM) was mixed with 20 μl 
samples of 1:26 homogenates in a cuvette and incubated for 5 min. Then oxaloacetate 
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(12.2 mM) was added and citrate synthase activity that catalyzes reaction of carbon 
acetyl CoA with carbon oxaloacetate was measured from 1 to 4 min at 412 nm. Enzyme 
activity was expressed as μmol/g/min. 
 
Measurement of total hydroperoxides 
The levels of total hydroperoxides as a marker of lipid peroxidation were 
measured as described previously (78). Briefly, lipid hydroperoxides were with FeSO4 in 
H2SO4 and a reactive dye (xylenol orange). The principle depends on the oxidation Fe2+ 
to Fe3+ when hydroperoxides are reduced. Ionized sulfuric acid assists the reduction and 
prevents spontaneous reaction of Fe2+ with xylenol orange, unless oxidized by 
hydroperoxides first. The Fe3+ reacted with the xylenol orange to form a Fe3+-xylenol 
complex purple in color. Diaphragm homogenates was mixed with 1mM FeSO4, 0.25M 
H2SO4, and 1mM Xylenol orange by twice inversion with parafilm. The mixture was 
then incubated at room temperature for 1 hour. Absorbance was then read at 580nm. 
Concentration of hydroperoxides was quantified against a tert-butyl hydroperoxide 
standard curve. 
 
Nuclear binding activity of NF-κB 
The nuclear binding activity of the p65 subunit of NF-κB in diaphragm muscle 
tissue homogenates was quantified using an ELISA-based method, TransAM NF-κB kit, 
according to the manufacturer’s instructions (Active motif: Carlsbad, CA). In brief, 20 
μg nuclear extract diluted in complete lysis buffer was loaded in the 96-well microplate 
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on which has been coated with oligonucleotide containing the NF-κB consensus binding 
site (5’-GGGACTTTCC-3’). Then the wells were incubated with a 100ul diluted anti-p65 
antiobody for 1 hour at room temperature without agitation. After three times washing 
with 200ul 1X washing buffer, 100 µl diluted HRP-conjugated secondary antibody were 
added to each well and incubated for an hour at room temperature. Sensitive colorimetric 
absorbance was quantified at 450nm with a reference wavelength of 655nm. 
 
Western immunoblot analysis 
Protein levels were measured by Western immunoblot analysis. Separating gel 
(375 mM Tris-HCl; pH=8.8; 0.4% sodium dodecyl sulfate (SDS); 10% acrylamide) and 
stacking gel (125 mM Tris-HCl; pH=6.8; 0.4% SDS; 10% acrylamide monomer) 
solutions were made, and polymerization then was initiated by N,N,N',N' - 
tetramethylethylene diamine (TEMED) and ammonium persulfate (APS). Separating and 
stacking gels were then quickly poured into a Bio-Rad Protein III gel-box (Bio-Rad, 
Hercules, CA). Twenty µg of protein from diaphragm homogenates in sample buffer 
(100 mM Tris-HCl, pH=6.8, 2% SDS, 30 mM dithiothreitol, 25% glycerol) were then 
loaded into the wells of the 10% SDS-PAGE gels, and electrophoresed at 150V for 60 
min. The gels were then transferred at 30V overnight onto a nitrocellulose membrane 
(Bio-Rad, Hercules, CA).  Membranes were blocked in 5% nonfat milk in PBS with 
0.1% Tween-20 for 7 hours. After blocking, membranes were incubated in phosphate-
buffered saline (PBS) at room temperature overnight with the appropriate primary 
antibodies: p65 (1:1,000). Following three washings in PBS with 0.4% Tween-20, 
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membranes were incubated with horseradish peroxidase–conjugated secondary 
antibodies in PBS at room temperature for 90 min. Following three washings in PBS 
with 0.4% Tween-20, an enhanced chemiluminescence (ECL) detection system 
(Amersham, Piscataway, NJ) were used for visualization. Densitometry and 
quantification were performed using a Kodak film cartridge, a scanner interfaced with a 
microcomputer, and the NIH Image J Analysis software program. To ensure equal 
loading of protein, Ponceau-S-staining were performed for each membrane. Membranes 
were stripped and reprobed for GAPDH (1:2000, Advanced Immunochemical) as 
“housekeeping” proteins to further confirm protein loading. 
 
Histochemistry 
Cross-sections (10 µm thick) were cut from the middle portion of diaphragm 
muscle strips in a cryostat (-15°C), placed on slides and air-dried for 30 min. To measure 
the fiber cross-sectional area (CSA), CSA variability and centralized nuclei, cross-
sections were stained with two drops of hematoxylin, incubated for 1 min at room 
temperature. Hematoxylin stains a bluish-purple color for myocytes and mitochondria, 
while nuclei stain dark blue. Stained sections were then rinsed with tapped water and air 
dried for 20 min before mounting with Vectamount medium (Vector Laboratories). 
Diaphragm cross-sectional images were visualized and captured using a Zeiss Axioplot 
Vision-series microscope and software program at a magnitude of 40X.  For 
measurement of muscle fiber cross-sectional area, muscle fiber membrane perimeters 
were traced and quantified using the NIH Image J Analysis software program. The total 
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average areas within the membrane outlines were used to determine the cross sectional 
area per unit and expressed in µm2. Muscle cell area was calibrated against images taken 
using a stage micrometer. 
 
Immunohistochemistry 
 Sample cross-sections were cut (10 µm thick) in a cryostat (-15°C) and fixed in 
cold acetone (-20°C) for 1 hour. After drying samples for 30 min, sections were blocked 
with 10% normal serum and 0.05% Tween 20 in TBS for 15 min. The desired primary 
antibodies: Macrophage (1:100), CD4+ (1:100), CD8+ (1:100), dystrophin (1:500), 
nNOS (1:500), α1-syntrophin (1:500), β-sarcoglycan (1:200) and α-dystrobrevin (1:500) 
were applied in blocking buffer and placed on the section for an hour. After washing, 
biotinylated secondary antibody were applied to the sections in PBS buffer for 30 min. 
Cross-sections were stained for 5 min with Vectastain elite ABC reagent and incubated 
in peroxidase substrate solution (Vector) at room temperature for approximately 10 min 
until desired stain intensity appears. Stained sections were then rinsed with PBS and air 
dried for 20 min before mounting with Vectamount medium. 
Images were captured on a Zeiss Axio-Vision-series microscope and software at 
a magnitude of 10X to 20X, and quantified using the NIH Image J program. To measure 
the proportional area of inflammatory cells stained, NIH image J program was used as 
described previously (http://rsb.info.nih.gov/ij/). After opening the image, the image was 
separated into the red/green/blue (RGB) windows. Using an automatic threshold 
function calculated by formula (average background + average object)/2), the area 
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fraction of color image was determined. For immunofluorescence, Alexa Fluor 488 
(green) IgG secondary antibody was used to detect the 4-hydroxynonenol (4-HNE) and 
DAPI (blue) was used to detect the all nuclei. 
 
Metachromatic ATPase Staining 
 The diaphragm muscle was cut on a crystat and stained using a metachromatic 
ATPase protocol modified from Kanatous et al (75) and Ogilvie & Feeback (108). Serial 
sections were placed in acidic (pH=4.3) and alkali (pH=10.5) myosin ATPase 
preincubation medium for 8 min in room temperature. After washing the sample three 
times with Tris buffer (18mM CaCl2, 45mM Trizma base, 55mM Tris HCl, pH=7.8) for 
2 min, the sections were incubated in Guth’s ATP solution (18mM CaCl2, 0.15% ATP, 
6.7% Sigma 221 buffer, pH=7.8) for 25 min. Then sections were washed 3 times in 1% 
calcium chloride solution for 2 min and counterstained in 0.1% toluidine blue solution 
for 90 sec. After brief washing with distilled water, samples were dehydrated with 95% 
ethanol, 100% ethanol (twice) for 5 min apiece, and then cleared twice in xylene for 5 
min apiece. 
 
In vitro muscle preparation and contractile measurements 
 The diaphragm muscle was studied to determine muscle contractile function. 
The isolated diaphragm muscle preparation used was similar to that described by Lawler 
et al (85) (Appendix 3). After the whole diaphragm was quickly removed (<30 sec 
without blood flow), muscle strips were placed in ice-cold (4°C) Krebs-Ringer solution 
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(118mM NaCl, 4.7mM KCl, 1.8mM CaCl2, 1.18mM MgSO4, 1.18mM KH2PO4, 25mM 
NaHCO3, and 11mM glucose, pH=7.4) aerated with a 95% O2, 5% CO2 gas mixture. 
Fiber bundles were cut parallel to the fibers leaving the lateral portion of the costal 
diaphragm with the rib intact on one end and the central tendon intact on the other end. 
The rib end of each diaphragm was tied to a glass rod supporter using silk 4-0 sutures, 
with another suture tied to the central tendon which was attached to an isometric force 
transducer (Grass FT03). Each fiber bundle was positioned in a temperature-controlled 
(36°C) muscle bath (Harvard Apparatus) containing Krebs-Ringer solution (pH=7.4).  
Tension was determined by a DC amplifier and displayed on a chart recorder 
(Allen Datagraph 2125E). Following a 10 minute thermo-equilibration period, 
diaphragm muscle was adjusted to optimal length (Lo) which coincides with the length 
at which isometric twitch forces are maximized. Fiber bundles were stimulated by field 
generation via two platinum foil electrodes driven by a Glass stimulator (S48). Stimulus 
trains were 250ms in duration and each pulse was 2.0trains/sec. Twitch, 20Hz (low-
frequency) and 150Hz (maximal isometric tension: Po) were used as a pulse paradigm to 
measure the contractile function of diaphragm muscle (86). After determination of Lo, 
the force production in response to stimulation at 20Hz and Po was measured. One 
minute was allowed between contractions to eliminate hysteresis.  
We also investigated the effect of a single exposure in vitro to EUK-134 on muscle 
contractility in diaphragm muscle fiber bundles. After baseline contractile properties 
(twitch, 20Hz, 150Hz) were measured in control Krebs solution (PRE), diaphragm fiber 
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bundles were placed in test media comprised of EUK-134 (50mM) in Krebs solution for 5 
min and contractile properties were measured for each fiber bundle (POST). 
At the completion of functional test, diaphragm muscle was removed from the 
bath, trimmed of tendon, and weighted on an analytical balance. Muscle mass and Lo 
were used to calculate muscle quality (N•cm-2) which is force normalized per total 
muscle cross-sectional area (muscle mass / [fiber length ⅹ 1.056]).  
 
Statistical analysis 
Data were analyzed with one-way ANOVA to determine the mean differences for 
each group. Student-Newman-Keuls test was performed for post hoc test. All values were 
presented as mean ± SEM. Statistical significance was set at P < 0.05 (Appendix 4). 
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CHAPTER III 
RESULTS 
 
Effect of EUK-134 treatment on body mass changes in wild type and 
mdx mice 
The body mass changes as an index of animal growth from 20- to 28-days old 
wild type and mdx mice are illustrated in Figure1 and Table 1. There is significant 
difference between mdx and wild type animals. In 20 days old, mdx mice weighted 
35.1% less than age-matched wild type mice (P<0.001). All mice treated with either 
saline or EUK-134 increased in body mass were observed following onset or during 
treatment periods. There was no difference in body mass change between saline-treated 
wild type mice and EUK-134 treated wild type mice. For saline-treated wild type mice, 
the body masses increased 74.2% from 20 days (9.086±0.458g) to 28 days 
(15.829±0.797g) of age. The body masses of EUK-134 treated wild type mice increased 
67.4% from 20 days (9.329±0.749g) to 28 days (15.617±1.129g). For saline-treated mdx 
mice, the body masses increased in 76.8% from 20 days (5.900±0.145g) to 28 days 
(10.429±0.480g). 8 days of EUK-134 treatment in the mdx mice resulted in increased the 
mean body mass about 113.5% from 20days (5.817±0.339g) to 28 days (12.05±0.598g). 
However, following EUK-134 treatment, body masses of mdx mice were higher with 
15.5 %, but not significantly different from the saline-treated mdx mice. 
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Figure 1. Effect of EUK-134 treatment on body mass changes in wild type 
and mdx mice. * indicates that saline-treated wild type mice (WS) is 
significantly different from saline-treated mdx mice (MS) (P<0.001).  
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Effect of EUK-134 treatment on diaphragm muscle mass and diaphragm 
muscle mass / body mass in wild type and mdx mice 
Diaphragm muscle mass was significantly lower in mdx mice than age-matched 
wild type mice (-42.2%, p<0.01) (Table 1). EUK-134 had a significant, positive effect in 
protecting against reduced diaphragm muscle mass in mdx mice (+61.2%, p<0.01).  
Moreover, EUK-134 treatment resulted in higher diaphragm muscle mass in the wild-
type mice (+57.3%, p<0.001). There was no difference in diaphragm muscle mass / body 
mass between mdx and wild type mice (Table 1). However, EUK-134 treatment 
increased diaphragm muscle mass/body mass in both mdx (+38.7%, p<0.01) and wild 
type mice (+60.0%, p<0.001). 
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Table 1. Effect of EUK-134 treatment on body mass, diaphragm mass and 
diaphragm muscle mass / body mass in wild type and mdx mice 
Body mass (BM) (g) 
Groups 
Before 
(20 days) 
After 
(28 days) 
Diaphragm 
muscle mass 
(DM)  
(g) 
DM/BM  
(mg/g) 
WS 9.086 ± 0.458 cd 15.829 ± 0.797 cd 0.056 ± 0.003 bc 3.544 ± 0.146 bd 
WE 9.329 ± 0.749 ab 15.617 ± 1.129 cd 0.088 ± 0.008 acd 5.669 ± 0.391 acd 
MS 5.900 ± 0.145 ab  10.429 ± 0.480 ab 0.032 ± 0.002 abd 3.112 ± 0.170 bd 
ME 5.817 ± 0.339 ab 12.050 ± 0.613 ab 0.052 ± 0.003 bc 4.316 ± 0.179 abc 
Data are expressed as mean ± SEM. BM, body mass; DM, diaphragm muscle 
mass; WS, wild type with saline; WE, wild type with EUK-134; MS, mdx 
with saline; ME, mdx with EUK-134. Indicating significant change relative to 
a: WS (P<0.05), b: WE (p<0.05), c: MS (p<0.05), d: ME (p<0.05) 
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Effect of EUK-134 treatment on diaphragm muscle cross-sectional area 
(CSA), CSA variability and internal nuclei in wild type and mdx mice 
Hematoxylin-stained histological characteristics of diaphragm muscle with mdx 
and wild type mice were illustrated in Figure 2. Diaphragm muscle cross-sectional area 
was significantly smaller in mdx mice than age-matched wild type mice (-23.3%, 
p<0.001) (Figure 3). There was no EUK-134 treatment effect on CSA changes in both 
mdx (696.39±12.29g vs. 694.78±18.77g) and wild type mice (858.45±11.20g vs. 
874.78±17.37g). Variability of diaphragm muscle cross sectional area was elevated in 
mdx mice (+37.3%) compared with wild type mice, but significantly reduced by EUK-
134 treatment in mdx mice (p<0.01) (Figure 4). Internal nuclei numbers per 100,000μm2 
were increased in mdx mice compared with wild type mice (p<0.001), and reduced by 
EUK-134 treatment in mdx mice (p<0.001) (Figure 5).  
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Figure 2. Hematoxylin-stained cross-sections of diaphragm in wild type and 
mdx mice. The diaphragm cross-sections (40X) were stained with 
hematoxylin from the following groups: wild type + saline (WS), wild type 
+ EUK-134 (WE), mdx + saline (MS), and mdx + EUK-134 (ME).  
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Figure 3. Effect of EUK-134 treatment on diaphragm muscle cross-sectional 
area (CSA) in wild type and mdx mice. Data are expressed as mean ± SEM. 
Indicating significant change relative to a: WS (P<0.05), b: WE (p<0.05), c: 
MS (p<0.05), d: ME (p<0.05). 
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Figure 4. Effect of EUK-134 treatment on diaphragm muscle CSA variability 
in wild type and mdx mice. Data are expressed as mean ± SEM. Indicating 
significant change relative to a: WS (P<0.05), b: WE (p<0.05), c: MS 
(p<0.05), d: ME (p<0.05). 
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Figure 5. Effect of EUK-134 treatment on # of internal nuclei in wild type and 
mdx mice. Data are expressed as mean ± SEM. Indicating significant change 
relative to a: WS (P<0.05), b: WE (p<0.05), c: MS (p<0.05), d: ME (p<0.05). 
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Effect of EUK-134 treatment on diaphragm fiber type changes in wild 
type and mdx mice 
Given that EUK-134 reversed diaphragm muscle damage, the depression of the 
mitochondrial oxidative enzyme citrate synthase and diaphragm muscle contractility in 
mdx mice, we sought to determine if EUK-134 also affect the fiber type proportion in 
diaphragm muscle. Type I fibers were darkly stained for acid ATPase, but lightly stained 
for alkaline ATPase. Adversely, type II fibers darkly are reactive for alkaline ATPase, 
lightly stained for acid ATPase. Type IIc fibers were moderately-to-darkly reactive for 
acid ATPase and moderately reactive for alkaline ATPase (Figure 6). The proportions of 
type I and type II fiber (%) were lower in saline-treated mdx mice than in saline-treated 
wild type mice (Table 2). There was no EUK-134 treatment effect in type I fiber 
composition changes both wild type and mdx mice (Table 2). Compared with saline-
treated mdx mice, EUK-134 treated mdx mice showed increase in type II fiber. The 
proportion of type IIc fiber (%) were higher in mdx mice compared with wild type mice, 
but significantly reduced by EUK-134 treatment in mdx mice (Table 2). 
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Figure 6. Effect of EUK-134 treatment on fiber type changes in wild type 
and mdx mice. Staining for myofibrillar ATPase (A, C, E, G: acid 
preincubation, pH 4.3; B, D, F, H: alkaline preincubation, pH 10.5) of 
cross sections from diaphragm muscles. Indicate that I : Type I fiber, II: 
Type II fiber, C: Type IIc fiber. 
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Table 2. Effect of EUK-134 treatment on changes in fiber type composition (%) 
in wild type and mdx mice 
Groups Type I Type II (a/b) Type IIc 
WS 8.365 ± 0.390 c 89.598 ± 0.227 c 2.037 ± 0.390 c 
WE 7.673 ± 0.200 90.633 ± 0.141 c 1.694 ± 0.165 c 
MS 6.789 ± 0.439 a 84.774 ± 1.473 abd 8.437 ± 1.507 abd 
ME 7.435 ± 0.400  87.964 ± 1.105 c 4.601 ± 1.167 c 
Data are expressed as mean ± SEM. WS, wild type with saline; WE, wild 
type with EUK-134; MS, mdx with saline; ME, mdx with EUK-134. 
Indicating significant change relative to a: WS (P<0.05), b: WE (p<0.05), 
c: MS (p<0.05), d: ME (p<0.05) 
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Effect of EUK-134 treatment on diaphragm muscle protein concentration 
and citrate synthase activity in wild type and mdx mice  
Figures 7 & 8 illustrate the soluble and nucleosome protein concentration of 
diaphragm muscle in mdx and wild type mice. There was significant decrease in soluble 
protein concentration in mdx mice compared with wild type mice (p<0.01) (Figure 7). 
However, EUK-134 treatment increased soluble protein concentration in mdx mice 
(p<0.001) (Figure 7). There was no difference in nucleosome protein concentration 
between saline-treated mdx and wild type mice (Figure 8). However, EUK-134 treatment 
increased nucleosome protein concentration in mdx mice (p<0.001) (Figure 8).  
Citrate synthase activity, a marker of oxidative capacity and indicative of 
mitochondrial density and function, was significantly lower in mdx mice (- 27.1%) 
compared with wild type mice, but increased with EUK-134 treatment in mdx mice 
(+42.8%, p<0.01) (Figure 9).  
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Figure 7. Effect of EUK-134 treatment on diaphragm muscle protein 
concentration (soluble) in wild type and mdx mice. Data are expressed as 
mean ± SEM. Indicating significant change relative to a: WS (P<0.05), b: 
WE (p<0.05), c: MS (p<0.05), d: ME (p<0.05). 
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Figure 8. Effect of EUK-134 treatment on diaphragm muscle protein 
concentration (nucleosome) in wild type and mdx mice. Data are expressed 
as mean ± SEM. Indicating significant change relative to a: WS (P<0.05), 
b: WE (p<0.05), c: MS (p<0.05), d: ME (p<0.05). 
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Figure 9. Effect of EUK-134 treatment on diaphragm muscle citrate 
synthase activity in wild type and mdx mice. Data are expressed as mean ± 
SEM. Indicating significant change relative to a: WS (P<0.05), b: WE 
(p<0.05), c: MS (p<0.05), d: ME (p<0.05). 
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Effect of EUK-134 treatment on oxidative stress in wild type and mdx mice  
Total hydroperoxide levels were significantly higher in mdx mice compared with 
wild type mice (+12.0 %, p<0.01) (Figure 10). In diaphragm muscle, total hydroperoxides 
were not different between saline-treated wild type and EUK-134 treated wild type mice. 
However, EUK-134 treatment in mdx mice blunted oxidative stress compared with 
saline-treated mdx mice, with total hydroperoxides that were not different with saline-
treated wild type mice. Localization of 4-HNE protein abducts in wild type and mdx 
mice were higher in both cytoplasms and nucleus (Figure 11). Compared with saline-
treated wild type, labeling density of 4-HNE in cytoplasm and nucleus was higher in 
saline-treated mdx mice. However, EUK-134 decreased labeling density of 4-HNE in 
mdx mice. 
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Figure 10. Effect of EUK-134 treatment on total hydroperoxides in wild type 
and mdx mice. Data are expressed as mean ± SEM. Indicating significant 
change relative to a: WS (P<0.05), b: WE (p<0.05), c: MS (p<0.05), d: ME 
(p<0.05). 
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Figure 11. Effect of EUK-134 treatment on localization of 4-hydroxynonenal 
(4-HNE) in wild type and mdx mice. 
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Effect of EUK-134 treatment on T-cells (CD4+ & CD8+) and macrophages 
in wild type and mdx mice 
To verify if EUK-134 treatment attenuated diaphragm muscle inflammation, we 
measured the immunoreactivity of T-cells (CD4+ & CD8+) and macrophages in the 
diaphragm muscles of 4 groups of mice at 28 days of age. Compared with saline-treated mdx 
mice, EUK-134 treated mdx mice showed substantial reduction of inflammation in the 
diaphragm highlighted by CD4+ and CD8+,  macrophages (CD11b) immunostaining 
(Figures 12-17). CD4+ immunoreactivity area (%) was higher in saline-treated mdx mice 
(+12.9% and +12.7%, respectively) than in saline-treated and EUK-134 treated wild type 
mice (Figures 13 & 14). EUK-134 treatment significantly reduced immunoreactivity of 
CD4+ in mdx mice (-6.3%) (Figure 13). CD8+ immunoreactivity area was higher in saline-
treated mdx mice (+15.0% and +14.9%, respectively) than in saline-treated and EUK-134 
treated wild type mice (Figures 14 & 15). Immunoreactive inflammation area of CD8+ was 
reduced in EUK-134 treated mdx mice compared with saline-treated mdx mice (-13.1%, 
p<0.001) (Figure 15). Macrophages immunoreactive area (%) was significantly higher in 
saline-treated mdx mice (+15.0% and +14.9%, respectively) than in saline-treated 
(p<0.001) and EUK-134 treated wild type mice (p<0.001) (Figures 16 & 17). Likewise, 
immunoreactive inflammation area (%) of macrophages was significantly reduced in 
EUK-134 treated mdx mice as compared with saline-treated mdx mice (-13.1%, p<0.01) 
(Figure 17). These findings demonstrated that EUK-134 significantly attenuated 
diaphragm inflammation associated with dystrophin-deficient mdx mice.  
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Figure 12. Effect of EUK-134 treatment on localization of CD4+ in wild 
type and mdx mice. Data are expressed as mean ± SEM. Indicating 
significant change relative to a: WS (P<0.05), b: WE (p<0.05), c: MS 
(p<0.05), d: ME (p<0.05). 
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Figure 13. Effect of EUK-134 treatment on CD4+ immunoreactivity in 
wild type and mdx mice. Data are expressed as mean ± SEM. Indicating 
significant change relative to a: WS (P<0.05), b: WE (p<0.05), c: MS 
(p<0.05), d: ME (p<0.05). 
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Figure 14. Effect of EUK-134 treatment on localization of CD8+ in wild 
type and mdx mice. Data are expressed as mean ± SEM. Indicating 
significant change relative to a: WS (P<0.05), b: WE (p<0.05), c: MS 
(p<0.05), d: ME (p<0.05). 
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Figure 15. Effect of EUK-134 treatment on CD8+ immunoreactivity in 
wild type and mdx mice. Data are expressed as mean ± SEM. Indicating 
significant change relative to a: WS (P<0.05), b: WE (p<0.05), c: MS 
(p<0.05), d: ME (p<0.05). 
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Figure 16. Effect of EUK-134 treatment on localization of macrophages in 
wild type and mdx mice. Data are expressed as mean ± SEM. Indicating 
significant change relative to a: WS (P<0.05), b: WE (p<0.05), c: MS 
(p<0.05), d: ME (p<0.05). 
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Figure 17. Effect of EUK-134 treatment on macrophages immunoreactivity 
in wild type and mdx mice. Data are expressed as mean ± SEM. Indicating 
significant change relative to a: WS (P<0.05), b: WE (p<0.05), c: MS 
(p<0.05), d: ME (p<0.05). 
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Effect of EUK-134 treatment on NF-kB p65 subunit DNA binding 
activity and protein levels in wild type and mdx mice  
NF-κB p65 subunit DNA binding activity was significantly higher in mdx mice 
compared with wild type mice (+14.6%) (Figure 18). EUK-134 treatment resulted in a 
significant decrease of NF-κB p65 subunit DNA binding activity in mdx mice (-7.6%) 
(Figure 18). To verify if NF-κB DNA binding activity is directly related to NF-κB p65 
subunit translocation, we measured the NF-κB p65 protein levels. The NF-κB p65 
protein levels in the nucleosome fraction were higher in mdx mice compared with wild 
type mice (+60.2%) (Figure 19). 8 days of EUK-134 treatment resulted in a significant 
reduction in NF-κB nucleosome protein levels in mdx (-47.1%), but not in wild type 
mice (Figure 19). 
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Figure 18. Effect of EUK-134 treatment on NF-kB p65 subunit DNA 
binding activity in nucleosome fraction of wild type and mdx mice. Data 
are expressed as mean ± SEM. Indicating significant change relative to a: 
WS (P<0.05), b: WE (p<0.05), c: MS (p<0.05), d: ME (p<0.05). 
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Figure 19. Effect of EUK-134 treatment on NF-kB p65 nucleosome protein 
levels in wild type and mdx mice. Data are expressed as mean ± SEM. 
Indicating significant change relative to a: WS (P<0.05), b: WE (p<0.05), c: 
MS (p<0.05), d: ME (p<0.05). 
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Effect of EUK-134 treatment on localization of dystrophin, nNOS and 
other cytoskeleal proteins in wild type and mdx mice 
The expression of dystrophin was detected at the sarcolemma in wild type mice, 
but completely absent in mdx mice (Figure 20). In mdx mice, nNOS was absent from the 
sarcolemma but expressed in the cytosol although in small amounts (Figure 21). 
Remarkably, EUK-134 partially restored nNOS back to the sarcolemmal cytoskeleton in 
mdx mice (Figure 21). The α1-syntrophin which anchors nNOS to sarcolemma was 
absent in mdx mice (Figure 22). However, EUK-134 partly relocated α1-syntrophin back 
to the sarcolemmal region in mdx mice (Figure 22). The α-dystrobrevin and β-
sarcoglycan were expressed sarcolemmal cytoskeleton in both wild type mice and mdx 
mice (Figures 23 & 24). There was no localization effect of EUK-134 on α-dystrobrevin 
and β-sarcoglycan in wild type and mdx mice (Figures 23 & 24). 
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Figure 20. Effect of EUK-134 treatment on localization of dystrophin in wild 
type and mdx mice. 
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Figure 21. Effect of EUK-134 treatment on localization of nNOS in wild 
type and mdx mice. 
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Figure 22. Effect of EUK-134 treatment on localization of α1-syntrophin in 
wild type and mdx mice. 
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Figure 23. Effect of EUK-134 treatment on localization of α-dystrobrevin in 
wild type and mdx mice. 
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Figure 24. Effect of EUK-134 treatment on localization of β-sarcoglycan in 
wild type and mdx mice. 
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Effect of EUK-134 treatment on diaphragm muscle contractile function 
in wild type and mdx mice  
Diaphragm muscle twitch (Lo), low frequency tension (20Hz) and maximal 
isometric tension (150Hz; Po) were higher in saline-treated wild type mice compared 
with saline-treated mdx mice (Figures 25-27). However, 8 days of EUK-134 treatment in 
mdx mice resulted in a significant increase in twitch, low frequency tension, and Po 
compared with saline-treated mdx mice (Figures 25-27).  
Remarkably, even a single exposure of EUK-134 (50mM) in vitro resulted in a 
significant increase in twitch (+71.2%) and low frequency tension (+58.2%), but without 
affecting Po (+2.4%) in saline-treated mdx diaphragm compared with each initial tension 
value (Figures 28-30). There were no significant effects of a single exposure of EUK-
134 on twitch (+6.6%, -16.9% and +5.4%, respectively), low frequency tension (+9.0%, 
-8.7% and +12.7%, respectively), and Po (+8.3%, +3.5% and +4.2%, respectively) in 
saline-treated wild type, EUK-134 treated wild type group and EUK-134 treated mdx 
group compared with each initial tension value (Figures 28-30). 
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Figure 25. Effect of EUK-134 treatment on twitch tension in wild type and 
mdx mice. Data are expressed as mean ± SEM. Indicating significant 
change relative to a: WS (P<0.05), b: MS (p<0.05), c: ME (p<0.05). 
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Figure 26. Effect of EUK-134 treatment on low-frequency tension (20Hz) 
in wild type and mdx mice. Data are expressed as mean ± SEM. Indicating 
significant change relative to a: WS (P<0.05), b: MS (p<0.05), c: ME 
(p<0.05). 
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Figure 27. Effect of EUK-134 treatment on maximal isometric tension (Po) 
in wild type and mdx mice. Data are expressed as mean ± SEM. Indicating 
significant change relative to a: WS (P<0.05), b: MS (p<0.05), c: ME 
(p<0.05). 
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Figure 28. Effect of a single exposure of EUK-134 (50mM) on twitch 
tension in wild type and mdx mice. Data are expressed as mean ± SEM. 
Indicating significant change relative to a: WS (P<0.05), b: MS (p<0.05), 
c: ME (p<0.05). 
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Figure 29. Effect of of a single exposure of EUK-134 (50mM) on low-
frequency tension (20Hz) in wild type and mdx mice. Data are expressed 
as mean ± SEM. Indicating significant change relative to a: WS (P<0.05), 
b: MS (p<0.05), c: ME (p<0.05). 
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Figure 30. Effect of a single exposure of EUK-134 (50mM) on maximal 
isometric tension (Po) in wild type and mdx mice. Data are expressed as 
mean ± SEM. Indicating significant change relative to a: WS (P<0.05), b: 
MS (p<0.05), c: ME (p<0.05). 
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CHAPTER IV 
DISCUSSION 
 
In the present study we evaluated the potential direct benefit of EUK-134 
treatment on diaphragm muscle morphology and function in dystrophin-deficient mdx 
mice and found the potential mechanisms involved in muscle damage and weakness. The 
rationale for this study was based on the proposed role of antioxidants [e.g., N-
acetylcysteine (NAC), epigallocatechin-3-gallate (EGCG), and low-iron diet] which 
attenuate muscle damage and improve contractile function in the progression of muscle 
pathologies in muscular dystrophy (16, 22, 165). The novel findings of this study include 
that antioxidant EUK-134 protects muscle damage and weakness against oxidative stress 
and inflammation and enhances cellular and functional properties in mdx diaphragm. 
We demonstrated that EUK-134 might protect against loss of body mass, 
diaphragm mass, diaphragm mass to body mass ratio in mdx mice. EUK-134 treatment 
in mdx mice resulted decreased internalized nuclei, cross-sectional area variability and 
type IIc fiber proportion, indicating that EUK-134 might ameliorate the dystrophic 
pathology by reducing muscle damage and degeneration in mdx mice. EUK-134, a 
specifically targeted antioxidant which can quench superoxide and hydrogen peroxide, 
also reduced some oxidative stress markers (e.g., total hydroperoxides and 4-HNE) in 
mdx diaphragm. 
We demonstrated that EUK-134 might protect against inflammation by 
decreasing infiltration of T-cells (e.g., CD4+ and CD8+) and macrophages (e.g., CD11b). 
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NF-κB p65 subunit DNA binding activity and p65 protein levels in nucleosome fraction 
were ameliorated in EUK-134 treated mdx diaphragm.  
EUK-134 also partially restored nNOS back to the sarcolemmal cytoskeleton, 
associated with relocation of α-1 syntrophin to myocyte periphery. In addition, specific 
force generation, particularly at twitch and low frequency tension (20Hz), was improved 
by 8 days of EUK-134 treatment as well as even a single exposure in vitro to EUK-134 
in mdx diaphragm. These highly novel data indicate that muscle damage and weakness 
including compromised muscle contractility and DAPC disassembly with DMD are 
partially regulated by redox-dependant mechanisms. 
To our knowledge, these are the first data to indicate that EUK-134 has a 
protective effect against muscle damage, inflammation, oxidative stress and contractile 
function in mdx diaphragm.  
 
Effect of EUK-134 on muscle damage 
In the present study we found that there is a significant reduction in body mass and 
diaphragm muscle mass of 20-28 day old mdx mice compared with age-matched wild type 
mice. Our findings are consistent with previous studies (38, 129), demonstrating that the 
reduction in body mass and muscle mass of mdx mice happens in early age (up to 2 
months) mainly due to larger proportion of small muscle fibers. Compared with 
retardation in ontogenetic development of mdx mice at early age, several investigators 
have noted that body mass and muscle mass are either increased or not different with age 
in mdx mice compared with wild type mice (37, 53, 58, 129, 143).  
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We found that EUK-134 partially increased the body mass in mdx mice (+15.5%) 
and significantly increased diaphragm muscle mass both in mdx and wild type mice (Table 
1). Interestingly, the degree of diaphragm muscle mass increase was greater than the 
degree of body mass increase, indicating that EUK-134 may protect against decrease in 
muscle mass to body mass ratio in mdx mice. However, increasing diaphragm muscle 
mass in EUK-134 treated wild type and mdx mice seem not occur as a result of muscle 
hypertrophy, as there was no EUK-134 treatment effect in diaphragm muscle cross-
sectional area both mdx and wild type mice (Figure 3). 
The ability of 8 days of EUK-134 treatment to improve the morphological 
characteristics and attenuate damage of diaphragm muscle in 4-week-old mdx mice are 
striking and novel finding. Based on the histological analysis in this study, EUK-134 
treatment in mdx mice substantially reduced fiber cross-sectional area variability (Figure 
4) and internalized nuclei (Figure 5), which are persistent indicators of fibers that have 
been damaged and experienced regeneration or repair.  
Moreover, we noted widespread presence of immature, undifferentiated 
regenerating muscle fibers in mdx mice with intermediate ATPase activity that 
contribute to differences between the fiber type distributions compared with wild type 
mice. EUK-134 treatment may contribute to ameliorate muscle damage and regeneration 
and induce fiber type changes in mdx mice (Figure 25). In the present study, the 
reduction in regenerative type IIc fibers in EUK-134 treated mdx mice indicates that 
antioxidant EUK-134 can ameliorate the dystrophic pathology by reducing the initial 
damage to dystrophic muscle, rather than increasing regeneration. 
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It has been noted that extensive muscle damage is accompanied by the activation, 
proliferation, and fusion of resident myogenic precursor cells (satellite cells), which 
reside between the sarcolemma and basal lamina. The ability of the satellite cells to be 
reactivated however, is limited and progressive replacement of damaged cells lead to the 
senescence of satellite cells with DMD human (15, 162) and mdx mice (91).   
Increased fatigue of respiratory muscles is a hallmark of human DMD as a result 
of disrupted mitochondrial metabolism and function with DMD (45, 48, 95). The current 
study showed that citrate synthase activity was decreased in mdx diaphragm (Figure 8), 
consistent with reduced oxidative capacity and mitochondrial density. Indeed, citrate 
synthase activity levels of diaphragm in EUK-134 treated mdx mice were similar to wild 
type controls (Figure 8). 
 
Effect of EUK-134 treatment on oxidative stress 
In the present study, we found that hydroperoxides and 4-HNE as lipid 
peroxidation endproduct markers were increased in 4-week-old mdx mice compared with 
wild type mice (Figures 9 & 10). Lipids are one of the most sensitive oxidation targets 
for reactive oxygen species (ROS) (81). Several reports have demonstrated that the 
amounts of lipid peroxidation are significantly increased in skeletal muscle and 
diaphragm of mdx mice and DMD patients compared with age-matched wild type 
controls (41, 69, 115). 
Disatnik et al (41) found that lipid peroxidation increased in skeletal muscle of 
15-20-day old mdx mice and demonstrated that oxidative stress levels rose in the 
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muscles at a pre-necrotic stage. Recently, Messina et al (99) established that lipid 
peroxidation inhibition attenuated tissue damage and enhanced muscle function in mdx 
mice. Nakae’s group (105) have reported the enhanced lipofuscin formation in 2- to 7-
year-old DMD muscle and 4-week-old mdx diaphragm, indicating that a product of 
oxidative injury of cellular macromolecules by oxygen-derived free radical and redox-
active metal ion accumulates at an early age in both DMD humans and mdx mice.  
In the present study, EUK-134 treatment decreased the lipid peroxidation in mdx 
diaphragm, indicating that the beneficial effects of EUK-134 on diaphragm function 
were a result of its properties as superoxide dismutase and catalase mimetic. It was 
demonstrated that muscles from mdx mice are more vulnerable to oxidative stress (40, 
41, 119). Thus, diminishing oxidative stress via antioxidants might protect muscles from 
damage and weakness in mdx mice. EUK-134 has antioxidant properties and appears to 
be potent scavengers of superoxide and hydrogen peroxide known for their damaging 
effects on macromolecular cells. 
In mormal muscles, neuronal nitric oxide (nNOS) also called muscle-specific 
isoform μNOS that catalyses nitric oxide (NO•) production is mostly present in the 
sarcolemma. However, nNOS is almost absent in dystrophin-deficient DMD and mdx 
muscles. In the present study, we showed that nNOS is not localized in sarcolemma in 
mdx diaphragm and antioxidant EUK-134 partially leads to restore nNOS back to the 
sarcolemma cytoskeleton, strongly indicating that cytoskeletal disruption with DMD is 
partially regulated in a redox-dependant manner. 
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Nitric oxide (NO•) has been shown to have both pro-oxidant and anti-oxidant 
properties (36, 101). NO• reacts with superoxide (O2-•) producing peroxynitrite (ONOO-), 
which regulates a number of pro-oxidant reactions including protein nitration. It has 
been demonstrated that the altered regulation of nNOS in dystrophic muscle can induce 
the toxic interaction of nitric oxide (NO•) and superoxide (O2-•) with the cell and 
contribute to necrotic degeneration (61). The antioxidant properties of NO• is related 
with its ability to combine with more reactive species and convert them to less reactive 
species. The reaction of nitric oxide (NO•) with lipid peroxyl radicals which terminates 
lipid peroxidation is an example of nitric oxide (NO•) as a role of antioxidant (169).  
Wehling et al (164) found that a muscle-specific nNOS transgene in mdx mice 
attenuates muscular dystrophy. They suggested that the loss of nNOS from sarcolemma 
in dystrophin-deficient muscles exacerbates membrane damage and inflammation. 
Although enhancing nitric oxide (NO•) production in dystrophin-deficient muscle can 
ameliorate muscle pathology (164) and nNOS deficiency can lead to recurrent ischemia-
reperfusion injury (118), the relationship between nitric oxide (NO•) and dystrophic 
pathology is not simple. Several previous observations have suggested that the 
possibility that lacking either NO production (29, 35) or α-1 syntrophin (73) do not 
develop a muscular dystrophy. However, these findings are consistent with a “two-hit 
hypothesis”, demonstrating that lack of nNOS exacerbates dystrophic pathology only in 
the presence of other defects associated with dystrophin-deficiency (118).  
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Effect of EUK-134 treatment on inflammation 
In the current study, diaphragm muscle from mdx mice exhibited elevated 
inflammatory cells including T-cells (CD4+ and CD8+) and macrophages. EUK-134 
significantly attenuated alterations in inflammatory cells (Figures 13-18). Interestingly, 
EUK-134 had no effect on infiltration of inflammatory cells in the diaphragm from wild-
type. These data indicate that EUK-134 functions as anti-inflammatory agent specifically 
in mdx mice, but not in wild-type mice. Our findings are consistent with those to Monici 
et al (103) and Spencer et al (135) who reported elevated inflammatory response of 
muscle in DMD human and mdx mice.  
In this study, we demonstrated the effects of antioxidant EUK-134 on NF-κB 
activation in mdx diaphragm (Figures 11 & 12). NF-κB activity of diaphragm muscle was 
upregulated in mdx mice compared with wild type mice, possibly through the generation 
of oxidative stress. NF-κB activation in dystrophin-deficient diaphragm muscle is 
associated with an increase of NF-κB p65 subunit DNA binding activity and p65 protein 
levels. This finding is consistent with previous studies (1, 82, 103), demonstrating the 
predominant role of NF-κB activation in dystrophin-deficient muscle pathology. 
The novel findings in this study that antioxidant EUK-134 downregulates NF-κB 
activation and protein levels in nucleosome show that ameliorated pathology in EUK-
134 treated mdx mice is highly regulated by redox dependant mechanism (Figures 11 & 
12). It is well documented that NF-κB as a potential biomarker of oxidative stress is 
activated by low levels of reactive oxygen species (ROS) and inhibited by antioxidants 
(130, 157). As reactive oxygen species (ROS) are generated under numerous 
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pathological conditions including muscular dystrophy, NF-κB activation may provide 
important insight into etiology of dystrophin-deficient muscle pathology. 
Indeed, antioxidant EUK-134 attenuated inflammatory responses in mdx mice. It 
has been demonstrated that inflammatory cells such as neutrophils and macrophages can 
produce reactive oxygen species (ROS) such as superoxide anion and hydrogen peroxide 
and it is thought that muscle-derived nitric oxide (NO) and antioxidants can scavenge 
reactive oxygen species (ROS) produced by inflammatory cells (106, 149). Wehling and 
colleagues (164) have proposed that NOS transgene ameliorated muscle damage and 
inflammatory cells in mdx mice. Our results, indicating that the inflammatory response 
was reduced in EUK-134 treated mdx mice, can be attributed to the reduced oxidative 
stress and partially relocated nNOS in sarcolemma.  
 
Effect of EUK-134 treatment on muscle contractility 
There is growing evidence that reactive oxygen species (ROS) and reactive 
nitrogen species (RNS) play a role in modulating contractile function in skeletal muscle 
(4, 77, 120). Reid (120) demonstrated that low levels of reactive oxygen species (ROS) 
are essential for optimal contractile function and the relationship between oxidative 
stress and contractile response in muscle is biphasic or reversed U shaped, indicating 
that low levels of oxidative stress enhances muscle contractility, while high levels do not 
they are above optimal levels of oxidative stress.  
The main finding of the present study that contractile dysfunction occurred in 
mdx diaphragm was shown by a significant decrease in twitch, low-frequency (20Hz), 
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maximal isometric tension (Po) (Figures 19-21). Our findings are consistent with 
previous studies (53, 57, 90, 92, 140), indicating that dystrophin-deficient muscles are 
susceptible to force generating failure and contractile deficit. Moreover, Dupont-
Versteegden et al (44) demonstrated that the degree of contractile impairment in mdx 
mice is greater in diaphragm muscle than in skeletal muscle. The impairment of 
contractile function in dystrophin-deficient muscles could have resulted from alteration 
in the step of excitation-contraction coupling to impaired interactions between 
contractile apparatus, actin and myosin as well as calcium related channels (90, 165). 
The present findings show that antioxidant EUK-134 treatment in mdx mice 
resulted in improved muscle contractile function as demonstrated by significantly 
increased twitch, low-frequency (20Hz), maximal isometric tension (Po) (Figures 19-21). 
Several reports have demonstrated that exogenous antioxidants such as DMSO, N-
acetylcysteine, superoxide dismutase, and catalse decreased force production in 
unfatigued muscle (121, 123, 124), but antioxidants also improved muscle contractility 
in fatigued or pathological status (122, 165).  
Recently, Whitehead et al (165) demonstrated that antioxidant N-acetylcysteine 
(NAC) reduced oxidative stress and inflammation and provided protection against 
stretched-induced force reduction in mdx diaphragm. It is thus plausible to speculate that 
the improvement of diaphragm muscle contractile function in EUK-134 treated mdx 
mice most likely resulted from the decrease in muscle damage, oxidative stress, and 
inflammation. Our data show that even a single exposure in vitro of EUK-134 (50mM) 
for 5 minutes elevated twitch and low-frequency contractility in mdx mice, which 
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strongly suggests that antioxidant EUK-134 can even acutely compensate the 
compromised muscle contractility and excitation-contraction coupling in mdx diaphragm 
(Figures 22-24). 
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CHAPTER V 
SUMMARY AND CONCLUSIONS 
 
This studies outlined in this dissertation provide new evidence of the effects of 
EUK-134 on muscle damage, inflammation, and contractile function in mdx diaphragm. 
The specific aims of this study were to i) identify the role of oxidative stress on functional 
and morphological properties in mdx diaphragm (ii) identify the role of oxidative stress on 
inflammatory signaling pathways in mdx diaphragm (iii) identify the role of oxidative stress 
on dislocation of nNOS, dystrophin-associated scaffolding proteins and contractile 
properties in mdx diaphragm.  
The results of this study demonstrated that dystropin-deficient diaphragm muscle 
was associated with muscle damage, weakness and degeneration/regeneration, and was 
also susceptible to oxidative stress. However, EUK-134 treatment provided the 
diaphragm muscle significant protection against muscle damage and weakness via 
maintaining muscle mass, oxidative capacity, muscle contractility and decreasing 
oxidative stress and inflammation in 28-day-old mdx mice. These finding suggest that 
oxidative stress may contribute to tissue damage and weakness and antioxidanat 
treatment in early stage of pathology may have important therapeutic value against 
respiratory muscle failure in patients suffering from DMD. 
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APPENDIX 
 
1. A integrative model for DMD and mdx pathology 
 
 110
2. Potential targets of EUK-134 in the diaphragm muscle cell  
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3. In vitro muscle preparation 
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4. Statistics 
 
Body mass changes 
 
Repeated Measures Analysis of Variance (ANOVA)                
   
The P value is < 0.0001, considered extremely significant. 
Variation among column means is significantly greater than expected by chance. 
 
Student-Newman-Keuls Multiple Comparisons Test 
 
Comparison Mean Difference  P value 
MS vs WE -4.6302 *** P<0.001 
MS vs WS -4.6873 *** P<0.001 
MS vs ME -1.2450 ns P>0.05 
ME vs WE -3.3852 ** P<0.01 
ME vs WS -3.4423 ** P<0.01 
WS vs WE 0.0571 ns P>0.05 
 
With Student-Newman-Keuls test, it is impossible to calculate confidence intervals. 
 
Intermediate calculations. ANOVA table 
  
Tests of Within-Subjects Effects 
 
Source  
of variation 
Degree  
of freedom 
Sum  
of squares  Mean square F 
Treatment 
Treatment*Group 
8 
24 
925.975 
20.895 
115.747 
0.871 
547.009 
4.115 
Residuals 176 37.242 0.212  
Total 208 984.112   
  
Tests of Between-Subjects Effects 
 
Source  
of variation 
Degree  
of freedom 
Sum  
of squares  Mean square F 
Intercept 
Group 
1 
3 
24092.836 
1021.999 
24092.836 
340.666 
1011.052 
14.296 
Residuals 22 524.248 23.829  
Total 26 25639.083   
 
 113
Diaphragm mass 
 
One-way Analysis of Variance (ANOVA)                
   
The P value is < 0.0001, considered extremely significant. 
Variation among column means is significantly greater than expected by chance. 
 
Student-Newman-Keuls Multiple Comparisons Test 
 
Comparison Mean Difference Q  P value 
MS vs WE -0.05557 13.167 *** P<0.001 
MS vs WS -0.02357 5.813 ** P<0.01 
MS vs ME -0.01974 4.677 ** P<0.01 
ME vs WE -0.03583 8.181 *** P<0.001 
ME vs WS -0.003833 0.9082 ns P>0.05 
WS vs WE -0.03200 7.582 *** P<0.001 
 
With Student-Newman-Keuls test, it is impossible to calculate confidence intervals. 
 
Intermediate calculations. ANOVA table 
  
Source  
of variation 
Degree  
of freedom 
Sum  
of squares  Mean square 
Treatments 
(between columns) 3 0.01012 0.003374 
Residuals 
(within columns) 22 0.002532 0.0001151 
Total 25 0.01265  
  
F = 29.309  = (MStreatment/MSresidual)  
 
Summary of Data                          
 
Group Numbers of Points 
Standard 
Mean 
Standard 
Error of 
Deviation 
Standard 
Error of 
Mean 
Standard 
Error of 
Median 
WS 7 0.05580 0.007778 0.002940 0.05780 
WE 6 0.08780 0.01862 0.007601 0.08845 
MS 7 0.03223 0.004647 0.001757 0.03220 
ME 6 0.05197 0.007832 0.003197 0.05250 
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Diaphragm mass to body mass 
 
One-way Analysis of Variance (ANOVA)                
   
The P value is < 0.0001, considered extremely significant. 
Variation among column means is significantly greater than expected by chance. 
 
Student-Newman-Keuls Multiple Comparisons Test 
 
Comparison Mean Difference q  P value 
MS vs WE -2.557 11.021 *** P<0.001 
MS vs ME -1.204 5.191 ** P<0.01 
MS vs WS -0.4321 1.939 ns P>0.05 
WS vs WE -2.124 9.158 *** P<0.001 
WS vs ME -0.7719 3.328 * P<0.05 
ME vs WE -1.353 5.618 *** P<0.001 
 
With Student-Newman-Keuls test, it is impossible to calculate confidence intervals. 
 
Intermediate calculations. ANOVA table 
  
Source  
of variation 
Degree  
of freedom 
Sum  
of squares  Mean square 
Treatments 
(between columns) 3 24.037 8.012 
Residuals 
(within columns) 22 7.649 0.3477 
Total 25 31.686  
  
F = 23.045 = (MStreatment/MSresidual)  
 
Summary of Data                          
 
Group Numbers of Points 
Standard 
Mean 
Standard 
Error of 
Deviation 
Standard 
Error of 
Mean 
Standard 
Error of 
Median 
WS 7 3.544 0.3865 0.1461 3.729 
WE 6 5.669 0.9575 0.3909 5.444 
MS 7 3.112 0.4484 0.1695 2.969 
ME 6 4.316 0.4386 0.1791 4.347 
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Diaphragm muscle cross-sectional area (CSA) 
 
One-way Analysis of Variance (ANOVA)                
   
The P value is < 0.0001, considered extremely significant. 
Variation among column means is significantly greater than expected by chance. 
 
Student-Newman-Keuls Multiple Comparisons Test 
 
Comparison Mean Difference q  P value 
ME vs WE -180.00 11.261 *** P<0.001 
ME vs WS -163.68 9.674 *** P<0.001 
ME vs MS -1.611 0.1005 ns P>0.05 
MS vs WE -178.39 10.176 *** P<0.001 
MS vs WS -162.06 8.814 *** P<0.001 
WS vs WE -16.325 0.8900 ns P>0.05 
 
With Student-Newman-Keuls test, it is impossible to calculate confidence intervals. 
 
Intermediate calculations. ANOVA table 
  
Source 
of variation 
Degree 
of freedom 
Sum 
of squares Mean square 
Treatments 
(between columns) 3 2.07307409e+7 6910247 
Residuals 
(within columns) 2854 5.78443605e+8 202678 
Total 2857 5.99174346e+8  
  
F = 34.095 = (MStreatment/MSresidual)  
 
Summary of Data                          
 
Group Numbers of Points 
Standard 
Mean 
Standard 
Error of 
Deviation 
Standard 
Error of 
Mean 
Standard 
Error of 
Median 
WS 552 858.45 263.24 11.204 823.50 
WE 663 874.78 447.31 17.372 758.00 
MS 656 696.39 314.83 12.292 635.00 
ME 987 694.78 589.70 18.770 569.00 
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CSA variability 
 
One-way Analysis of Variance (ANOVA)                
   
The P value is 0.0037, considered very significant. 
Variation among column means is significantly greater than expected by chance. 
 
Student-Newman-Keuls Multiple Comparisons Test 
 
Comparison Mean Difference q  P value 
WS vs MS -72.257 4.187 * P<0.05 
WS vs ME -6.589 0.3798 ns P>0.05 
WS vs WE -0.7728 --- ns P>0.05 
WE vs MS -71.4843 4.142 * P<0.05 
WE vs ME -5.817 --- ns P>0.05 
ME vs MS -65.668 4.243 ** P<0.01 
 
With Student-Newman-Keuls test, it is impossible to calculate confidence intervals. 
 
Intermediate calculations. ANOVA table 
  
Source 
of variation 
Degree 
of freedom 
Sum 
of squares Mean square 
Treatments 
(between columns) 3 127595 42532 
Residuals 
(within columns) 121 1086729 8981.2 
Total 124 1214325  
  
F = 4.736 = (MStreatment/MSresidual)  
 
Summary of Data                          
 
Group Numbers of Points 
Standard 
Mean 
Standard 
Error of 
Deviation 
Standard 
Error of 
Mean 
Standard 
Error of 
Median 
WS 25 193.75 40.811 8.162 188.73 
WE 25 194.52 90.748 18.150 185.76 
MS 38 266.00 126.43 20.509 222.15 
ME 37 200.34 84.607 13.909 186.11 
 
 117
Internal nuclei 
 
One-way Analysis of Variance (ANOVA)                
   
The P value is < 0.0001, considered extremely significant. 
Variation among column means is significantly greater than expected by chance. 
 
Student-Newman-Keuls Multiple Comparisons Test 
 
Comparison Mean Difference q  P value 
WE vs MS -7.893 15.959 *** P<0.001 
WE vs ME -4.064 8.367 *** P<0.001 
WE vs WS -0.3146 0.5732 ns P>0.05 
WS vs MS -7.578 14.247 *** P<0.001 
WS vs ME -3.749 7.160 *** P<0.001 
ME vs MS -3.829 8.208 *** P<0.001 
 
With Student-Newman-Keuls test, it is impossible to calculate confidence intervals. 
 
Intermediate calculations. ANOVA table 
  
Source 
of variation 
Degree 
of freedom 
Sum 
of squares Mean square 
Treatments 
(between columns) 3 1330.2 443.39 
Residuals 
(within columns) 126 1026.6 8.148 
Total 129 2356.8  
  
F = 54.417 = (MStreatment/MSresidual)  
 
Summary of Data                          
 
Group Numbers of Points 
Standard 
Mean 
Standard 
Error of 
Deviation 
Standard 
Error of 
Mean 
Standard 
Error of 
Median 
WS 24 1.009 1.740 0.3552 0.000 
WE 31 0.6942 1.197 0.2149 0.000 
MS 36 8.587 4.396 0.7326 8.060 
ME 39 4.758 2.501 0.4005 5.380 
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Type I fiber (%) 
 
One-way Analysis of Variance (ANOVA)                
   
The P value is 0.0359, considered significant. 
Variation among column means is significantly greater than expected by chance. 
 
Student-Newman-Keuls Multiple Comparisons Test 
 
Comparison Mean Difference q  P value 
MS vs WS -1.576 4.270 * P<0.05 
MS vs WE -0.8839 2.394 ns P>0.05 
MS vs ME -0.6465 --- ns P>0.05 
ME vs WS -0.9295 2.518 ns P>0.05 
ME vs WE -0.2373 --- ns P>0.05 
WE vs WS -0.6921 --- ns P>0.05 
 
With Student-Newman-Keuls test, it is impossible to calculate confidence intervals. 
 
Intermediate calculations. ANOVA table 
  
Source 
of variation 
Degree 
of freedom 
Sum 
of squares Mean square 
Treatments 
(between columns) 3 15.247 5.082 
Residuals 
(within columns) 44 71.943 1.635 
Total 47 87.191  
  
F = 3.108 = (MStreatment/MSresidual)  
 
Summary of Data                          
 
Group Numbers of Points 
Standard 
Mean 
Standard 
Error of 
Deviation 
Standard 
Error of 
Mean 
Standard 
Error of 
Median 
WS 12 8.365 1.350 0.3898 7.836 
WE 12 7.673 0.6937 0.2003 7.526 
MS 12 6.789 1.521 0.4390 7.147 
ME 12 7.435 1.387 0.4003 7.719 
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Type II fiber (%) 
 
One-way Analysis of Variance (ANOVA)                
   
The P value is 0.0042, considered very significant. 
Variation among column means is significantly greater than expected by chance. 
 
Student-Newman-Keuls Multiple Comparisons Test 
 
Comparison Mean Difference Q  P value 
MS vs WE -5.859 6.298 ** P<0.01 
MS vs WS -4.824 5.186 ** P<0.01 
MS vs ME -3.190 3.429 * P<0.05 
ME vs WE -2.669 2.869 ns P>0.05 
ME vs WS -1.634 --- ns P>0.05 
WS vs WE -1.035 --- ns P>0.05 
 
With Student-Newman-Keuls test, it is impossible to calculate confidence intervals. 
 
Intermediate calculations. ANOVA table 
  
Source 
of variation 
Degree 
of freedom 
Sum 
of squares Mean square 
Treatments 
(between columns) 3 78.640 26.213 
Residuals 
(within columns) 12 41.543 3.462 
Total 15 120.18  
  
F = 7.572 = (MStreatment/MSresidual)  
 
Summary of Data                          
 
Group Numbers of Points 
Standard 
Mean 
Standard 
Error of 
Deviation 
Standard 
Error of 
Mean 
Standard 
Error of 
Median 
WS 4 89.598 0.4546 0.2273 89.481 
WE 4 90.633 0.2810 0.1405 90.682 
MS 4 84.774 2.945 1.473 85.134 
ME 4 87.964 2.211 1.105 88.942 
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Type IIc fiber (%) 
 
One-way Analysis of Variance (ANOVA)                
   
The P value is 0.0001, considered extremely significant. 
Variation among column means is significantly greater than expected by chance. 
 
Student-Newman-Keuls Multiple Comparisons Test 
 
Comparison Mean Difference Q  P value 
WE vs MS -6.743 6.907 *** P<0.001 
WE vs ME -2.906 2.977 ns P>0.05 
WE vs WS -0.3424 --- ns P>0.05 
WS vs MS -6.400 6.556 *** P<0.001 
WS vs ME -2.564 --- ns P>0.05 
ME vs MS -3.836 3.930 ** P<0.01 
 
With Student-Newman-Keuls test, it is impossible to calculate confidence intervals. 
 
Intermediate calculations. ANOVA table 
  
Source 
of variation 
Degree 
of freedom 
Sum 
of squares Mean square 
Treatments 
(between columns) 3 232.57 77.522 
Residuals 
(within columns) 28 213.47 7.624 
Total 31 446.04  
  
F = 10.168 = (MStreatment/MSresidual)  
 
Summary of Data                          
 
Group Numbers of Points 
Standard 
Mean 
Standard 
Error of 
Deviation 
Standard 
Error of 
Mean 
Standard 
Error of 
Median 
WS 8 2.037 1.103 0.3901 2.512 
WE 8 1.694 0.4658 0.1647 1.732 
MS 8 8.437 4.262 1.507 7.719 
ME 8 4.601 3.301 1.167 3.083 
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Soluble protein concentration 
 
One-way Analysis of Variance (ANOVA)                
   
The P value is 0.0071, considered very significant. 
Variation among column means is significantly greater than expected by chance. 
 
Student-Newman-Keuls Multiple Comparisons Test 
 
Comparison Mean Difference Q  P value 
MS vs WE -4.817 4.536 * P<0.05 
MS vs WS -4.490 4.402 ** P<0.01 
MS vs ME -2.942 2.884 * P<0.05 
ME vs WE -1.874 1.765 ns P>0.05 
ME vs WS -1.548 --- ns P>0.05 
WS vs WE -0.3262 --- ns P>0.05 
 
With Student-Newman-Keuls test, it is impossible to calculate confidence intervals. 
 
Intermediate calculations. ANOVA table 
  
Source 
of variation 
Degree 
of freedom 
Sum 
of squares Mean square 
Treatments 
(between columns) 3 196.74 65.579 
Residuals 
(within columns) 50 728.42 14.568 
Total 53 925.15  
  
F = 4.501 = (MStreatment/MSresidual)  
 
Summary of Data                          
 
Group Numbers of Points 
Standard 
Mean 
Standard 
Error of 
Deviation 
Standard 
Error of 
Mean 
Standard 
Error of 
Median 
WS 14 36.033 4.027 1.076 36.848 
WE 12 36.360 3.184 0.9193 36.291 
MS 14 31.543 4.622 1.235 31.708 
ME 14 34.485 3.142 0.8398 35.498 
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Nucleosome protein concentration 
 
One-way Analysis of Variance (ANOVA)                
   
The P value is 0.0001, considered extremely significant. 
Variation among column means is significantly greater than expected by chance. 
 
Student-Newman-Keuls Multiple Comparisons Test 
 
Comparison Mean Difference Q  P value 
WS vs ME -3.482 6.470 *** P<0.001 
WS vs WE -0.8743 1.561 ns P>0.05 
WS vs MS -0.5165 --- ns P>0.05 
MS vs ME -2.966 5.510 *** P<0.001 
MS vs WE -0.3578 --- ns P>0.05 
WE vs ME -2.608 4.655 ** P<0.01 
 
With Student-Newman-Keuls test, it is impossible to calculate confidence intervals. 
 
Intermediate calculations. ANOVA table 
  
Source 
of variation 
Degree 
of freedom 
Sum 
of squares Mean square 
Treatments 
(between columns) 3 100.84 33.615 
Residuals 
(within columns) 50 202.79 4.056 
Total 53 303.64  
  
F = 8.288 = (MStreatment/MSresidual)  
 
Summary of Data                          
 
Group Numbers of Points 
Standard 
Mean 
Standard 
Error of 
Deviation 
Standard 
Error of 
Mean 
Standard 
Error of 
Median 
WS 14 15.609 1.768 0.4725 15.685 
WE 12 16.483 2.087 0.6024 15.875 
MS 14 16.126 2.158 0.5767 15.230 
ME 14 19.091 2.033 0.5432 18.669 
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Citrate synthase activity 
 
One-way Analysis of Variance (ANOVA)                
   
The P value is 0.0076, considered very significant. 
Variation among column means is significantly greater than expected by chance. 
 
Student-Newman-Keuls Multiple Comparisons Test 
 
Comparison Mean Difference Q  P value 
MS vs ME -4.379 5.055 ** P<0.01 
MS vs WS -3.809 4.397 * P<0.05 
MS vs WE -3.142 3.485 * P<0.05 
WE vs ME -1.237 1.372 ns P>0.05 
WE vs WS -0.6667 --- ns P>0.05 
WS vs ME -0.5700 --- ns P>0.05 
 
With Student-Newman-Keuls test, it is impossible to calculate confidence intervals. 
 
Intermediate calculations. ANOVA table 
  
Source 
of variation 
Degree 
of freedom 
Sum 
of squares Mean square 
Treatments 
(between columns) 3 80.133 26.711 
Residuals 
(within columns) 23 120.82 5.253 
Total 26 200.95  
  
F = 5.085 = (MStreatment/MSresidual)  
 
Summary of Data                          
 
Group Numbers of Points 
Standard 
Mean 
Standard 
Error of 
Deviation 
Standard 
Error of 
Mean 
Standard 
Error of 
Median 
WS 7 14.050 2.098 0.7929 14.470 
WE 6 13.383 2.928 1.196 14.260 
MS 7 10.241 2.689 1.016 10.560 
ME 7 14.620 1.165 0.4402 14.840 
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Total hydroperoxides 
 
One-way Analysis of Variance (ANOVA)                
   
The P value is 0.0075, considered very significant. 
Variation among column means is significantly greater than expected by chance. 
 
Student-Newman-Keuls Multiple Comparisons Test 
 
Comparison Mean Difference Q  P value 
WS vs MS -79.044 5.089 ** P<0.01 
WS vs ME -28.005 1.803 ns P>0.05 
WS vs WE -8.887 --- ns P>0.05 
WE vs MS -70.157 4.340 * P<0.05 
WE vs ME -19.117 --- ns P>0.05 
ME vs MS -51.040 3.286 * P<0.05 
 
With Student-Newman-Keuls test, it is impossible to calculate confidence intervals. 
 
Intermediate calculations. ANOVA table 
  
Source 
of variation 
Degree 
of freedom 
Sum 
of squares Mean square 
Treatments 
(between columns) 3 25838 8612.6 
Residuals 
(within columns) 23 38843 1688.8 
Total 26 64681  
  
F = 5.100 = (MStreatment/MSresidual)  
 
Summary of Data                          
 
Group Numbers of Points 
Standard 
Mean 
Standard 
Error of 
Deviation 
Standard 
Error of 
Mean 
Standard 
Error of 
Median 
WS 7 660.01 18.332 6.929 655.99 
WE 6 668.90 13.468 5.498 667.71 
MS 7 739.06 31.280 11.823 733.12 
ME 7 688.02 70.768 26.748 678.30 
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CD4+ immunoreactivity 
 
One-way Analysis of Variance (ANOVA)                
   
The P value is < 0.0001, considered extremely significant. 
Variation among column means is significantly greater than expected by chance. 
 
Student-Newman-Keuls Multiple Comparisons Test 
 
Comparison Mean Difference Q  P value 
WS vs MS -12.936 7.689 *** P<0.001 
WS vs ME -6.636 3.803 * P<0.05 
WS vs WE -0.2451 0.1499 ns P>0.05 
WE vs MS -12.691 8.427 *** P<0.001 
WE vs ME -6.391 4.056 ** P<0.01 
ME vs MS -6.300 3.877 ** P<0.01 
 
With Student-Newman-Keuls test, it is impossible to calculate confidence intervals. 
 
Intermediate calculations. ANOVA table 
  
Source 
of variation 
Degree 
of freedom 
Sum 
of squares Mean square 
Treatments 
(between columns) 3 2200.1 733.36 
Residuals 
(within columns) 71 3445.3 48.526 
Total 74 5645.4  
  
F = 15.113 = (MStreatment/MSresidual)  
 
Summary of Data                          
 
Group Numbers of Points 
Standard 
Mean 
Standard 
Error of 
Deviation 
Standard 
Error of 
Mean 
Standard 
Error of 
Median 
WS 15 8.453 6.781 1.751 8.043 
WE 23 8.698 7.187 1.499 9.966 
MS 20 21.389 4.649 1.040 21.518 
ME 17 15.089 8.854 2.148 13.568 
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CD8+ immunoreactivity 
 
One-way Analysis of Variance (ANOVA)                
   
The P value is < 0.0001, considered extremely significant. 
Variation among column means is significantly greater than expected by chance. 
 
Student-Newman-Keuls Multiple Comparisons Test 
 
Comparison Mean Difference Q  P value 
WS vs MS -14.961 10.417 *** P<0.001 
WS vs ME -1.863 1.133 ns P>0.05 
WS vs WE -0.02179 --- ns P>0.05 
WE vs MS -14.939 10.023 *** P<0.001 
WE vs ME -6.391 4.056 ** P<0.01 
ME vs MS -6.300 3.877 ** P<0.01 
 
With Student-Newman-Keuls test, it is impossible to calculate confidence intervals. 
 
Intermediate calculations. ANOVA table 
  
Source 
of variation 
Degree 
of freedom 
Sum 
of squares Mean square 
Treatments 
(between columns) 3 3821.1 1273.7 
Residuals 
(within columns) 75 3436.3 45.817 
Total 78 7257.4  
  
F = 27.800 = (MStreatment/MSresidual)  
 
Summary of Data                          
 
Group Numbers of Points 
Standard 
Mean 
Standard 
Error of 
Deviation 
Standard 
Error of 
Mean 
Standard 
Error of 
Median 
WS 18 4.530 4.577 1.079 1.555 
WE 16 4.551 3.328 0.8321 2.581 
MS 29 19.491 9.560 1.775 21.933 
ME 16 6.393 4.865 1.216 6.671 
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Macrophages immunoreactivity 
 
One-way Analysis of Variance (ANOVA)                
   
The P value is < 0.0001, considered extremely significant. 
Variation among column means is significantly greater than expected by chance. 
 
Student-Newman-Keuls Multiple Comparisons Test 
 
Comparison Mean Difference Q  P value 
WE vs MS -14.910 6.863 *** P<0.001 
WE vs ME -8.043 3.702 * P<0.05 
WE vs WS -1.322 0.5625 ns P>0.05 
WS vs MS -13.588 7.494 *** P<0.001 
WS vs ME -6.721 3.707 * P<0.05 
ME vs MS -6.867 4.357 ** P<0.01 
 
With Student-Newman-Keuls test, it is impossible to calculate confidence intervals. 
 
Intermediate calculations. ANOVA table 
  
Source 
of variation 
Degree 
of freedom 
Sum 
of squares Mean square 
Treatments 
(between columns) 3 2735.1 911.69 
Residuals 
(within columns) 79 5494.0 69.544 
Total 82 8229.1  
  
F = 13.109 = (MStreatment/MSresidual)  
 
Summary of Data                          
 
Group Numbers of Points 
Standard 
Mean 
Standard 
Error of 
Deviation 
Standard 
Error of 
Mean 
Standard 
Error of 
Median 
WS 17 7.789 5.359 1.300 9.075 
WE 10 6.467 7.773 2.458 1.391 
MS 28 21.377 11.334 2.142 22.469 
ME 28 14.510 6.153 1.163 14.933 
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NF-κB p65 DNA binding activity 
 
One-way Analysis of Variance (ANOVA)                
   
The P value is 0.0020, considered very significant. 
Variation among column means is significantly greater than expected by chance. 
 
Student-Newman-Keuls Multiple Comparisons Test 
 
Comparison Mean Difference Q  P value 
WS vs MS -0.2629 6.303 *** P<0.001 
WS vs ME -0.1171 2.809 ns P>0.05 
WS vs WE -0.09690 --- ns P>0.05 
WE vs MS -0.1660 3.823 * P<0.05 
WE vs ME -0.02024 --- ns P>0.05 
ME vs MS -0.1457 3.494 * P<0.05 
 
With Student-Newman-Keuls test, it is impossible to calculate confidence intervals. 
 
Intermediate calculations. ANOVA table 
  
Source 
of variation 
Degree 
of freedom 
Sum 
of squares Mean square 
Treatments 
(between columns) 3 0.2469 0.08230 
Residuals 
(within columns) 23 0.2800 0.01217 
Total 26 0.5269  
  
F = 6.761 = (MStreatment/MSresidual)  
 
Summary of Data                          
 
Group Numbers of Points 
Standard 
Mean 
Standard 
Error of 
Deviation 
Standard 
Error of 
Mean 
Standard 
Error of 
Median 
WS 7 1.800 0.1020 0.03856 1.798 
WE 6 1.897 0.1364 0.05568 1.906 
MS 7 2.063 0.1172 0.04430 2.051 
ME 7 1.918 0.08374 0.03165 1.924 
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NF-κB p65 nucleosome protein levels 
 
One-way Analysis of Variance (ANOVA)                
   
The P value is 0.0216, considered significant. 
Variation among column means is significantly greater than expected by chance. 
 
Student-Newman-Keuls Multiple Comparisons Test 
 
Comparison Mean Difference Q  P value 
ME vs MS -619.67 4.612 * P<0.05 
ME vs WE -315.00 2.345 ns P>0.05 
ME vs WS -125.17 --- ns P>0.05 
WS vs MS -494.50 3.681 * P<0.05 
WS vs WE -189.83 --- ns P>0.05 
WE vs MS -304.67 2.268 ns P>0.05 
 
With Student-Newman-Keuls test, it is impossible to calculate confidence intervals. 
 
Intermediate calculations. ANOVA table 
  
Source 
of variation 
Degree 
of freedom 
Sum 
of squares Mean square 
Treatments 
(between columns) 3 1308401 436134 
Residuals 
(within columns) 20 2165847 108292 
Total 23 3474248  
  
F = 4.027 = (MStreatment/MSresidual)  
 
Summary of Data                          
 
Group Numbers of Points 
Standard 
Mean 
Standard 
Error of 
Deviation 
Standard 
Error of 
Mean 
Standard 
Error of 
Median 
WS 6 820.83 344.40 140.60 717.00 
WE 6 1010.7 392.70 160.32 1051.0 
MS 6 1315.3 287.89 117.53 1227.5 
ME 6 695.67 278.31 113.62 709.00 
 
 130
Twitch 
 
One-way Analysis of Variance (ANOVA)                
   
The P value is 0.0007, considered extremely significant. 
Variation among column means is significantly greater than expected by chance. 
 
Student-Newman-Keuls Multiple Comparisons Test 
 
Comparison Mean Difference Q  P value 
MS vs WS -1.544 6.854 *** P<0.001 
MS vs WE -1.036 4.601 ** P<0.01 
MS vs ME -0.8393 3.726 * P<0.05 
ME vs WS -0.7047 2.926 ns P>0.05 
ME vs WE -0.1970 --- ns P>0.05 
WE vs WS -0.5077 --- ns P>0.05 
 
With Student-Newman-Keuls test, it is impossible to calculate confidence intervals. 
 
Intermediate calculations. ANOVA table 
  
Source 
of variation 
Degree 
of freedom 
Sum 
of squares Mean square 
Treatments 
(between columns) 3 8.783 2.928 
Residuals 
(within columns) 22 7.655 0.3480 
Total 25 16.438  
  
F = 8.413 = (MStreatment/MSresidual)  
 
Summary of Data                          
 
Group Numbers of Points 
Standard 
Mean 
Standard 
Error of 
Deviation 
Standard 
Error of 
Mean 
Standard 
Error of 
Median 
WS 6 1.776 1.026 0.4190 1.936 
WE 6 1.268 0.08608 0.03514 1.242 
MS 8 0.2320 0.1883 0.066581 0.1625 
ME 6 1.071 0.6486 0.2648 0.9990 
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Low frequency tension (20Hz) 
 
One-way Analysis of Variance (ANOVA)                
   
The P value is 0.0009, considered extremely significant. 
Variation among column means is significantly greater than expected by chance. 
 
Student-Newman-Keuls Multiple Comparisons Test 
 
Comparison Mean Difference Q  P value 
MS vs WS -2.208 6.678 *** P<0.001 
MS vs ME -1.365 4.129 * P<0.05 
MS vs WE -1.339 4.050 ** P<0.01 
WE vs WS -0.8687 2.458 ns P>0.05 
WE vs ME -0.02600 --- ns P>0.05 
ME vs WS -0.8427 --- ns P>0.05 
 
With Student-Newman-Keuls test, it is impossible to calculate confidence intervals. 
 
Intermediate calculations. ANOVA table 
  
Source 
of variation 
Degree 
of freedom 
Sum 
of squares Mean square 
Treatments 
(between columns) 3 17.773 5.924 
Residuals 
(within columns) 22 16.483 0.7492 
Total 25 34.256  
  
F = 7.908 = (MStreatment/MSresidual)  
 
Summary of Data                          
 
Group Numbers of Points 
Standard 
Mean 
Standard 
Error of 
Deviation 
Standard 
Error of 
Mean 
Standard 
Error of 
Median 
WS 6 2.614 1.329 0.5426 2.848 
WE 6 1.745 0.2826 0.1154 1.829 
MS 8 0.4065 0.3088 0.1092 0.3230 
ME 6 1.771 1.148 0.4685 1.780 
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Maximal isometric tension (Po) 
 
One-way Analysis of Variance (ANOVA)                
   
The P value is 0.0002, considered extremely significant. 
Variation among column means is significantly greater than expected by chance. 
 
Student-Newman-Keuls Multiple Comparisons Test 
 
Comparison Mean Difference Q  P value 
MS vs WS -9.385 7.653 *** P<0.001 
MS vs WE -6.557 5.347 ** P<0.01 
MS vs ME -4.482 3.654 * P<0.05 
ME vs WS -4.903 3.740 * P<0.05 
ME vs WE -2.075 1.583 ns P>0.05 
WE vs WS -2.828 2.157 ns P>0.05 
 
With Student-Newman-Keuls test, it is impossible to calculate confidence intervals. 
 
Intermediate calculations. ANOVA table 
  
Source 
of variation 
Degree 
of freedom 
Sum 
of squares Mean square 
Treatments 
(between columns) 3 329.39 109.80 
Residuals 
(within columns) 22 226.89 10.313 
Total 25 556.28  
  
F = 10.646 = (MStreatment/MSresidual)  
 
Summary of Data                          
 
Group Numbers of Points 
Standard 
Mean 
Standard 
Error of 
Deviation 
Standard 
Error of 
Mean 
Standard 
Error of 
Median 
WS 6 11.227 5.284 2.157 13.383 
WE 6 8.399 1.044 0.4263 8.120 
MS 8 1.842 1.147 0.4054 1.894 
ME 6 6.324 3.812 1.556 7.221 
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Twitch in single exposure of EUK-134 
 
One-way Analysis of Variance (ANOVA)                
   
The P value is 0.0001, considered extremely significant. 
Variation among column means is significantly greater than expected by chance. 
 
Student-Newman-Keuls Multiple Comparisons Test 
 
Comparison Mean Difference Q  P value 
WE vs MS -88.107 7.470 *** P<0.001 
WE vs WS -23.520 1.865 ns P>0.05 
WE vs ME -22.383 --- ns P>0.05 
ME vs MS -65.723 5.572 ** P<0.01 
ME vs WS -1.137 --- ns P>0.05 
WS vs MS -64.587 5.476 *** P<0.001 
 
With Student-Newman-Keuls test, it is impossible to calculate confidence intervals. 
 
Intermediate calculations. ANOVA table 
  
Source 
of variation 
Degree 
of freedom 
Sum 
of squares Mean square 
Treatments 
(between columns) 3 31468 10489 
Residuals 
(within columns) 22 20987 953.97 
Total 25 52456  
  
F = 10.996 = (MStreatment/MSresidual)  
 
Summary of Data                          
 
Group Numbers of Points 
Standard 
Mean 
Standard 
Error of 
Deviation 
Standard 
Error of 
Mean 
Standard 
Error of 
Median 
WS 6 106.57 12.141 4.956 106.86 
WE 6 83.053 6.282 2.565 86.250 
MS 8 171.16 53.468 18.904 152.15 
ME 6 105.44 2.873 1.173 106.00 
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Low frequency tension (20Hz) in single exposure of EUK-134 
 
One-way Analysis of Variance (ANOVA)                
   
The P value is 0.0008, considered extremely significant. 
Variation among column means is significantly greater than expected by chance. 
 
Student-Newman-Keuls Multiple Comparisons Test 
 
Comparison Mean Difference Q  P value 
WE vs MS -66.859 6.483 *** P<0.001 
WE vs ME -21.363 1.938 ns P>0.05 
WE vs WS -17.729 --- ns P>0.05 
WS vs MS -49.130 4.764 ** P<0.01 
WS vs ME -3.634 --- ns P>0.05 
ME vs MS -45.496 4.412 ** P<0.01 
 
With Student-Newman-Keuls test, it is impossible to calculate confidence intervals. 
 
Intermediate calculations. ANOVA table 
  
Source 
of variation 
Degree 
of freedom 
Sum 
of squares Mean square 
Treatments 
(between columns) 3 17616 5871.8 
Residuals 
(within columns) 22 16044 729.28 
Total 25 33660  
  
F = 8.052 = (MStreatment/MSresidual)  
 
Summary of Data                          
 
Group Numbers of Points 
Standard 
Mean 
Standard 
Error of 
Deviation 
Standard 
Error of 
Mean 
Standard 
Error of 
Median 
WS 6 109.04 20.228 8.258 100.00 
WE 6 91.313 5.750 2.347 93.620 
MS 8 158.17 44.374 15.689 144.92 
ME 6 112.68 3.152 1.287 111.36 
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Maximal isometric tension (Po) in single exposure of EUK-134 
 
One-way Analysis of Variance (ANOVA)                
   
The P value is 0.5345, considered not significant. 
Variation among column means is not significantly greater than expected by chance. 
 
Post tests 
Post tests were not calculated because the P value was greater than 0.05. 
 
Intermediate calculations. ANOVA table 
  
Source 
of variation 
Degree 
of freedom 
Sum 
of squares Mean square 
Treatments 
(between columns) 3 128.68 42.894 
Residuals 
(within columns) 22 1259.7 57.259 
Total 25 1388.4  
  
F = 0.7491 = (MStreatment/MSresidual)  
 
Summary of Data                          
 
Group Numbers of Points 
Standard 
Mean 
Standard 
Error of 
Deviation 
Standard 
Error of 
Mean 
Standard 
Error of 
Median 
WS 6 108.30 8.956 3.656 103.55 
WE 6 103.46 8.009 3.270 98.430 
MS 8 102.40 8.763 3.098 102.22 
ME 6 104.19 0.2890 0.1180 104.11 
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